US20230204593A1 - Microvesicle histone h2ax as a biomarker for genotoxic stress - Google Patents
Microvesicle histone h2ax as a biomarker for genotoxic stress Download PDFInfo
- Publication number
- US20230204593A1 US20230204593A1 US18/058,683 US202218058683A US2023204593A1 US 20230204593 A1 US20230204593 A1 US 20230204593A1 US 202218058683 A US202218058683 A US 202218058683A US 2023204593 A1 US2023204593 A1 US 2023204593A1
- Authority
- US
- United States
- Prior art keywords
- microvesicle
- h2ax
- cancer
- biological sample
- microvesicles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 231100000024 genotoxic Toxicity 0.000 title claims abstract description 33
- 230000001738 genotoxic effect Effects 0.000 title claims abstract description 33
- 108010033040 Histones Proteins 0.000 title description 10
- 239000000090 biomarker Substances 0.000 title description 9
- 101150044041 h2ax gene Proteins 0.000 title 1
- 102100034533 Histone H2AX Human genes 0.000 claims abstract description 148
- 238000000034 method Methods 0.000 claims abstract description 103
- 239000012472 biological sample Substances 0.000 claims abstract description 102
- 238000012360 testing method Methods 0.000 claims abstract description 75
- 238000012544 monitoring process Methods 0.000 claims abstract description 33
- 101001067891 Homo sapiens Histone H2AX Proteins 0.000 claims abstract 21
- 206010028980 Neoplasm Diseases 0.000 claims description 132
- 201000011510 cancer Diseases 0.000 claims description 110
- 238000011282 treatment Methods 0.000 claims description 74
- 239000003153 chemical reaction reagent Substances 0.000 claims description 70
- 210000001519 tissue Anatomy 0.000 claims description 36
- 239000002246 antineoplastic agent Substances 0.000 claims description 14
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 10
- 210000002381 plasma Anatomy 0.000 claims description 9
- 238000002965 ELISA Methods 0.000 claims description 8
- 206010073306 Exposure to radiation Diseases 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 239000012624 DNA alkylating agent Substances 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 5
- 235000013336 milk Nutrition 0.000 claims description 5
- 239000008267 milk Substances 0.000 claims description 5
- 210000004080 milk Anatomy 0.000 claims description 5
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 5
- 206010003445 Ascites Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 210000004381 amniotic fluid Anatomy 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
- 210000003128 head Anatomy 0.000 claims description 4
- 210000004880 lymph fluid Anatomy 0.000 claims description 4
- 210000003739 neck Anatomy 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 230000000241 respiratory effect Effects 0.000 claims description 4
- 210000003296 saliva Anatomy 0.000 claims description 4
- 210000001179 synovial fluid Anatomy 0.000 claims description 4
- 210000001138 tear Anatomy 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 229940126161 DNA alkylating agent Drugs 0.000 claims description 3
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 claims description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims description 3
- 229930013930 alkaloid Natural products 0.000 claims description 3
- 230000000340 anti-metabolite Effects 0.000 claims description 3
- 229940100197 antimetabolite Drugs 0.000 claims description 3
- 239000002256 antimetabolite Substances 0.000 claims description 3
- 238000011109 contamination Methods 0.000 claims description 3
- 230000007613 environmental effect Effects 0.000 claims description 3
- 238000000684 flow cytometry Methods 0.000 claims description 3
- 231100000446 genotoxin Toxicity 0.000 claims description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 3
- 230000002611 ovarian Effects 0.000 claims description 3
- 150000003505 terpenes Chemical class 0.000 claims description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 150000003057 platinum Chemical class 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 description 88
- 102000004169 proteins and genes Human genes 0.000 description 87
- 235000018102 proteins Nutrition 0.000 description 86
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 56
- 229960004964 temozolomide Drugs 0.000 description 56
- 210000004027 cell Anatomy 0.000 description 43
- 230000035882 stress Effects 0.000 description 24
- 239000011324 bead Substances 0.000 description 22
- 239000011347 resin Substances 0.000 description 19
- 229920005989 resin Polymers 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- 239000012091 fetal bovine serum Substances 0.000 description 16
- 239000000872 buffer Substances 0.000 description 15
- 238000001514 detection method Methods 0.000 description 15
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 14
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 239000000499 gel Substances 0.000 description 13
- 238000001962 electrophoresis Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- AVWQQPYHYQKEIZ-UHFFFAOYSA-K trisodium;2-dodecylbenzenesulfonate;3-dodecylbenzenesulfonate;4-dodecylbenzenesulfonate Chemical compound [Na+].[Na+].[Na+].CCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1.CCCCCCCCCCCCC1=CC=CC(S([O-])(=O)=O)=C1.CCCCCCCCCCCCC1=CC=CC=C1S([O-])(=O)=O AVWQQPYHYQKEIZ-UHFFFAOYSA-K 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 102000006947 Histones Human genes 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000012737 fresh medium Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000011550 stock solution Substances 0.000 description 8
- 239000013595 supernatant sample Substances 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 7
- 102100039869 Histone H2B type F-S Human genes 0.000 description 7
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 7
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000004202 carbamide Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- -1 vahrubicin Chemical compound 0.000 description 6
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 210000001808 exosome Anatomy 0.000 description 5
- 239000011536 extraction buffer Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 208000005017 glioblastoma Diseases 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102100025222 CD63 antigen Human genes 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 4
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 4
- 208000007641 Pinealoma Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 201000010881 cervical cancer Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 4
- 210000003463 organelle Anatomy 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 201000000849 skin cancer Diseases 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 208000008732 thymoma Diseases 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
- NMNDQBZTIMGTSF-UHFFFAOYSA-N 11h-indeno[1,2-h]isoquinoline Chemical compound C1=CN=CC2=C3CC4=CC=CC=C4C3=CC=C21 NMNDQBZTIMGTSF-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010003571 Astrocytoma Diseases 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000031448 Genomic Instability Diseases 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
- 208000000172 Medulloblastoma Diseases 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 108010047956 Nucleosomes Proteins 0.000 description 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 3
- 108010026552 Proteome Proteins 0.000 description 3
- 239000012722 SDS sample buffer Substances 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- 230000002583 anti-histone Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001163 endosome Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229960004961 mechlorethamine Drugs 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 210000001623 nucleosome Anatomy 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- NHKRDSRSZLLBTM-UHFFFAOYSA-N C1=CC=CC2=C3C=C(C=CC=C4)C4=C3NC=C21 Chemical compound C1=CC=CC2=C3C=C(C=CC=C4)C4=C3NC=C21 NHKRDSRSZLLBTM-UHFFFAOYSA-N 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 208000037138 Central nervous system embryonal tumor Diseases 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 2
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010014967 Ependymoma Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 208000017259 Extragonadal germ cell tumor Diseases 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 102000017286 Histone H2A Human genes 0.000 description 2
- 108050005231 Histone H2A Proteins 0.000 description 2
- 101710195517 Histone H2AX Proteins 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 206010023825 Laryngeal cancer Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 201000010133 Oligodendroglioma Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 2
- 206010061934 Salivary gland cancer Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- 201000009365 Thymic carcinoma Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 229940122803 Vinca alkaloid Drugs 0.000 description 2
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 2
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000012520 frozen sample Substances 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 235000004213 low-fat Nutrition 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 108010071421 milk fat globule Proteins 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 206010073131 oligoastrocytoma Diseases 0.000 description 2
- 208000021284 ovarian germ cell tumor Diseases 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 208000010626 plasma cell neoplasm Diseases 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000012508 resin bead Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 229960001055 uracil mustard Drugs 0.000 description 2
- 208000037965 uterine sarcoma Diseases 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- GCILEJUNEYIABW-UHFFFAOYSA-N v5t7s4hp8a Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2C=2C(=O)C3=CC=4OCOC=4C=C3C=2N1CCCN1C=CN=C1 GCILEJUNEYIABW-UHFFFAOYSA-N 0.000 description 2
- 206010046885 vaginal cancer Diseases 0.000 description 2
- 208000013139 vaginal neoplasm Diseases 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- RZACZDPZLLKYQQ-UHFFFAOYSA-N (2,3,8-trimethoxy-6-methyl-5,11-dioxoindeno[1,2-c]isoquinolin-9-yl) methanesulfonate Chemical compound CN1C(=O)C2=CC(OC)=C(OC)C=C2C(C2=O)=C1C1=C2C=C(OS(C)(=O)=O)C(OC)=C1 RZACZDPZLLKYQQ-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- PJOHVEQSYPOERL-SHEAVXILSA-N (e)-n-[(4r,4as,7ar,12br)-3-(cyclopropylmethyl)-9-hydroxy-7-oxo-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a-yl]-3-(4-methylphenyl)prop-2-enamide Chemical compound C1=CC(C)=CC=C1\C=C\C(=O)N[C@]1(CCC(=O)[C@@H]2O3)[C@H]4CC5=CC=C(O)C3=C5[C@]12CCN4CC1CC1 PJOHVEQSYPOERL-SHEAVXILSA-N 0.000 description 1
- WQRIYRHZKAWLAB-UHFFFAOYSA-N 15,16-dimethoxy-20-[(4-methoxyphenyl)methyl]-5,7-dioxa-20-azapentacyclo[10.8.0.02,10.04,8.013,18]icosa-1(12),2,4(8),9,13,15,17-heptaene-11,19-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C2=CC(OC)=C(OC)C=C2C(C(=O)C2=C3)=C1C2=CC1=C3OCO1 WQRIYRHZKAWLAB-UHFFFAOYSA-N 0.000 description 1
- USNYAFVSTLYFRK-UHFFFAOYSA-N 2,3-dimethoxy-6-methyl-8,9-bis(phenylmethoxy)indeno[1,2-c]isoquinoline-5,11-dione Chemical compound C=1C=CC=CC=1COC=1C=C2C=3N(C)C(=O)C=4C=C(OC)C(OC)=CC=4C=3C(=O)C2=CC=1OCC1=CC=CC=C1 USNYAFVSTLYFRK-UHFFFAOYSA-N 0.000 description 1
- NOVLAOFIZCBTLO-UHFFFAOYSA-N 20-(4-hydroxypentyl)-15,16-dimethoxy-5,7-dioxa-15-azapentacyclo[10.8.0.02,10.04,8.013,18]icosa-1(12),2,4(8),9,13(18),16-hexaene-11,19-dione Chemical compound O=C1C2=CC=3OCOC=3C=C2C(C(CCCC(C)O)C2=O)=C1C1=C2C=C(OC)N(OC)C1 NOVLAOFIZCBTLO-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- WHNPOQXWAMXPTA-UHFFFAOYSA-N 3-methylbut-2-enamide Chemical compound CC(C)=CC(N)=O WHNPOQXWAMXPTA-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 102100027271 40S ribosomal protein SA Human genes 0.000 description 1
- STAIUWUHIBGWFJ-UHFFFAOYSA-N 6-cyclopropylindeno[1,2-c]isoquinoline-5,11-dione Chemical compound O=C1C2=CC=CC=C2C2=C1C1=CC=CC=C1C(=O)N2C1CC1 STAIUWUHIBGWFJ-UHFFFAOYSA-N 0.000 description 1
- MXFQAZZHZMQRRV-UHFFFAOYSA-N 6-ethylindeno[1,2-c]isoquinoline-5,11-dione Chemical compound C12=CC=CC=C2C(=O)N(CC)C2=C1C(=O)C1=CC=CC=C12 MXFQAZZHZMQRRV-UHFFFAOYSA-N 0.000 description 1
- FDXWVBHHUWPWBT-UHFFFAOYSA-N 6-methyl-8,9-bis(phenylmethoxy)indeno[1,2-c]isoquinoline-5,11-dione Chemical compound C=1C=CC=CC=1COC=1C=C2C(=O)C=3C4=CC=CC=C4C(=O)N(C)C=3C2=CC=1OCC1=CC=CC=C1 FDXWVBHHUWPWBT-UHFFFAOYSA-N 0.000 description 1
- XTNSBPFEFLVLBC-UHFFFAOYSA-N 6-propylindeno[1,2-c]isoquinoline-5,11-dione Chemical compound C12=CC=CC=C2C(=O)N(CCC)C2=C1C(=O)C1=CC=CC=C12 XTNSBPFEFLVLBC-UHFFFAOYSA-N 0.000 description 1
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 208000032484 Accidental exposure to product Diseases 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100037982 Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Human genes 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010073360 Appendix cancer Diseases 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 201000008271 Atypical teratoid rhabdoid tumor Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 102100027221 CD81 antigen Human genes 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 102100024155 Cadherin-11 Human genes 0.000 description 1
- 102100029756 Cadherin-6 Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000005403 Casein Kinases Human genes 0.000 description 1
- 108010031425 Casein Kinases Proteins 0.000 description 1
- 102100028003 Catenin alpha-1 Human genes 0.000 description 1
- 102100028914 Catenin beta-1 Human genes 0.000 description 1
- 102000038594 Cdh1/Fizzy-related Human genes 0.000 description 1
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 description 1
- 102100031667 Cell adhesion molecule-related/down-regulated by oncogenes Human genes 0.000 description 1
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 description 1
- 102100034790 Centrosomal protein of 76 kDa Human genes 0.000 description 1
- 101710184857 Centrosomal protein of 76 kDa Proteins 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 108010058432 Chaperonin 60 Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 1
- SXVPOSFURRDKBO-UHFFFAOYSA-N Cyclododecanone Chemical compound O=C1CCCCCCCCCCC1 SXVPOSFURRDKBO-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 201000008228 Ependymoblastoma Diseases 0.000 description 1
- 206010014968 Ependymoma malignant Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 208000012468 Ewing sarcoma/peripheral primitive neuroectodermal tumor Diseases 0.000 description 1
- 102100040834 FXYD domain-containing ion transport regulator 5 Human genes 0.000 description 1
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 101150014889 Gad1 gene Proteins 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 102100035902 Glutamate decarboxylase 1 Human genes 0.000 description 1
- 102000013704 Glycine receptor beta Human genes 0.000 description 1
- 108050003545 Glycine receptor beta Proteins 0.000 description 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 101150043239 HSPA8 gene Proteins 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102100035960 Hedgehog-interacting protein Human genes 0.000 description 1
- 101710164669 Hedgehog-interacting protein Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 102100027363 Histone H2A type 2-C Human genes 0.000 description 1
- 102100021639 Histone H2B type 1-K Human genes 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 102100030634 Homeobox protein OTX2 Human genes 0.000 description 1
- 101000694288 Homo sapiens 40S ribosomal protein SA Proteins 0.000 description 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
- 101000951392 Homo sapiens Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000762236 Homo sapiens Cadherin-11 Proteins 0.000 description 1
- 101000794604 Homo sapiens Cadherin-6 Proteins 0.000 description 1
- 101000859063 Homo sapiens Catenin alpha-1 Proteins 0.000 description 1
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 description 1
- 101000777781 Homo sapiens Cell adhesion molecule-related/down-regulated by oncogenes Proteins 0.000 description 1
- 101000623903 Homo sapiens Cell surface glycoprotein MUC18 Proteins 0.000 description 1
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 1
- 101000893718 Homo sapiens FXYD domain-containing ion transport regulator 5 Proteins 0.000 description 1
- 101001027380 Homo sapiens Fibroblast growth factor 9 Proteins 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 101001009465 Homo sapiens Histone H2A type 2-C Proteins 0.000 description 1
- 101000898898 Homo sapiens Histone H2B type 1-K Proteins 0.000 description 1
- 101000584400 Homo sapiens Homeobox protein OTX2 Proteins 0.000 description 1
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 1
- 101001044438 Homo sapiens Intraflagellar transport protein 52 homolog Proteins 0.000 description 1
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 1
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 description 1
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101000604005 Homo sapiens NPC1-like intracellular cholesterol transporter 1 Proteins 0.000 description 1
- 101000738243 Homo sapiens Patched domain-containing protein 4 Proteins 0.000 description 1
- 101000878221 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP8 Proteins 0.000 description 1
- 101000611888 Homo sapiens Platelet-derived growth factor C Proteins 0.000 description 1
- 101000986265 Homo sapiens Protein MTSS 1 Proteins 0.000 description 1
- 101000842302 Homo sapiens Protein-cysteine N-palmitoyltransferase HHAT Proteins 0.000 description 1
- 101000692878 Homo sapiens Regulator of MON1-CCZ1 complex Proteins 0.000 description 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
- 101000577874 Homo sapiens Stromelysin-2 Proteins 0.000 description 1
- 101000577877 Homo sapiens Stromelysin-3 Proteins 0.000 description 1
- 101001074042 Homo sapiens Transcriptional activator GLI3 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 101000742579 Homo sapiens Vascular endothelial growth factor B Proteins 0.000 description 1
- 101000742596 Homo sapiens Vascular endothelial growth factor C Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 101000666874 Homo sapiens Visinin-like protein 1 Proteins 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 102100032832 Integrin alpha-7 Human genes 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 1
- 102100032999 Integrin beta-3 Human genes 0.000 description 1
- 101710100121 Intermediate filament protein A Proteins 0.000 description 1
- 102100022470 Intraflagellar transport protein 52 homolog Human genes 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- 102100039648 Lactadherin Human genes 0.000 description 1
- 101710191666 Lactadherin Proteins 0.000 description 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 208000004059 Male Breast Neoplasms Diseases 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
- 206010025557 Malignant fibrous histiocytoma of bone Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 102100030417 Matrilysin Human genes 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 102100032977 Myelin-associated oligodendrocyte basic protein Human genes 0.000 description 1
- 101710091862 Myelin-associated oligodendrocyte basic protein Proteins 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 102100038441 NPC1-like intracellular cholesterol transporter 1 Human genes 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 102000001775 Neurogranin Human genes 0.000 description 1
- 108010015301 Neurogranin Proteins 0.000 description 1
- 102000004207 Neuropilin-1 Human genes 0.000 description 1
- 108090000772 Neuropilin-1 Proteins 0.000 description 1
- 108090000770 Neuropilin-2 Proteins 0.000 description 1
- 102100037591 Neuroserpin Human genes 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 206010033268 Ovarian low malignant potential tumour Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 102100037887 Patched domain-containing protein 4 Human genes 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102100036978 Peptidyl-prolyl cis-trans isomerase FKBP8 Human genes 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010050487 Pinealoblastoma Diseases 0.000 description 1
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 1
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 1
- 102100040681 Platelet-derived growth factor C Human genes 0.000 description 1
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102100028951 Protein MTSS 1 Human genes 0.000 description 1
- 102100034433 Protein kinase C-binding protein NELL2 Human genes 0.000 description 1
- 102100030616 Protein-cysteine N-palmitoyltransferase HHAT Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 102100026436 Regulator of MON1-CCZ1 complex Human genes 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 102100028848 Stromelysin-2 Human genes 0.000 description 1
- 102100028847 Stromelysin-3 Human genes 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108010055170 Synaptotagmin I Proteins 0.000 description 1
- 102000001317 Synaptotagmin I Human genes 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 108700031126 Tetraspanins Proteins 0.000 description 1
- 102000043977 Tetraspanins Human genes 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 102100035559 Transcriptional activator GLI3 Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108030003004 Triphosphatases Proteins 0.000 description 1
- 108700030796 Tsg101 Proteins 0.000 description 1
- 101150072717 Tsg101 gene Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 102000003786 Vesicle-associated membrane protein 2 Human genes 0.000 description 1
- 108090000169 Vesicle-associated membrane protein 2 Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 102100038287 Visinin-like protein 1 Human genes 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 description 1
- 108010088665 Zinc Finger Protein Gli2 Proteins 0.000 description 1
- 102100035535 Zinc finger protein GLI1 Human genes 0.000 description 1
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 231100000818 accidental exposure Toxicity 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 208000014619 adult acute lymphoblastic leukemia Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 238000004082 amperometric method Methods 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 208000021780 appendiceal neoplasm Diseases 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000008873 bone osteosarcoma Diseases 0.000 description 1
- 208000012172 borderline epithelial tumor of ovary Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000002583 cell-derived microparticle Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- FFHRKNJYASWDCJ-UHFFFAOYSA-N chembl140724 Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2C=2C(=O)C3=CC=4OCOC=4C=C3C=2N1CC1=CC=CC=C1 FFHRKNJYASWDCJ-UHFFFAOYSA-N 0.000 description 1
- UCHLNKDNDLAVIF-UHFFFAOYSA-N chembl141180 Chemical compound C12=CC=CC=C2C(=O)N(CCCC)C2=C1C(=O)C1=CC(OCO3)=C3C=C12 UCHLNKDNDLAVIF-UHFFFAOYSA-N 0.000 description 1
- OKCIVKFJZUXQJQ-UHFFFAOYSA-N chembl142177 Chemical compound C12=CC=CC=C2C(=O)N(C)C2=C1C(=O)C1=CC(OCO3)=C3C=C12 OKCIVKFJZUXQJQ-UHFFFAOYSA-N 0.000 description 1
- AAKJFXMHQQBKFI-UHFFFAOYSA-M chembl316437 Chemical compound [Cl-].C1C2=CC=3OCOC=3C=C2C2=C1C1=CC(OC)=C(OC)C=C1C=[N+]2CC AAKJFXMHQQBKFI-UHFFFAOYSA-M 0.000 description 1
- HNHFPJGAYCKXBP-UHFFFAOYSA-N chembl342813 Chemical compound C12=CC(OC)=C(OC)C=C2C(=O)N(CC)C2=C1C(=O)C1=CC(OCO3)=C3C=C12 HNHFPJGAYCKXBP-UHFFFAOYSA-N 0.000 description 1
- DOBJCFZZJDMIKS-UHFFFAOYSA-N chembl342937 Chemical compound C12=CC(OC)=C(OC)C=C2C(=O)N(CCCC)C2=C1C(=O)C1=CC(OCO3)=C3C=C12 DOBJCFZZJDMIKS-UHFFFAOYSA-N 0.000 description 1
- ZQOKSNOLDMYSAQ-UHFFFAOYSA-N chembl356262 Chemical compound O=C1C2=CC=3OCOC=3C=C2C2=C1C(C=C(C(=C1)OC)OC)=C1C(=O)N2CCCCO ZQOKSNOLDMYSAQ-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 208000018805 childhood acute lymphoblastic leukemia Diseases 0.000 description 1
- 201000011633 childhood acute lymphocytic leukemia Diseases 0.000 description 1
- 201000002687 childhood acute myeloid leukemia Diseases 0.000 description 1
- 208000023973 childhood bladder carcinoma Diseases 0.000 description 1
- 201000004018 childhood brain stem glioma Diseases 0.000 description 1
- 208000026046 childhood carcinoid tumor Diseases 0.000 description 1
- 208000015632 childhood ependymoma Diseases 0.000 description 1
- 201000006392 childhood kidney cancer Diseases 0.000 description 1
- 208000016661 childhood malignant kidney neoplasm Diseases 0.000 description 1
- 201000005793 childhood medulloblastoma Diseases 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 210000002726 cyst fluid Anatomy 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000000572 ellipsometry Methods 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- FMFIFGLHVOZDEL-UHFFFAOYSA-N indotecan Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2C=2C(=O)C3=CC=4OCOC=4C=C3C=2N1CCCN1CCOCC1 FMFIFGLHVOZDEL-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 108010092830 integrin alpha7beta1 Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000005305 interferometry Methods 0.000 description 1
- 210000005049 internexin Anatomy 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 201000003175 male breast cancer Diseases 0.000 description 1
- 208000010907 male breast carcinoma Diseases 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000008203 medulloepithelioma Diseases 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 230000008172 membrane trafficking Effects 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000037970 metastatic squamous neck cancer Diseases 0.000 description 1
- YZLBGCGHCZWAON-UHFFFAOYSA-N methyl 2-(5,11-dioxoindeno[1,2-c]isoquinolin-6-yl)acetate Chemical compound C12=CC=CC=C2C(=O)N(CC(=O)OC)C2=C1C(=O)C1=CC=CC=C12 YZLBGCGHCZWAON-UHFFFAOYSA-N 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- QXYYYPFGTSJXNS-UHFFFAOYSA-N mitozolomide Chemical compound N1=NN(CCCl)C(=O)N2C1=C(C(=O)N)N=C2 QXYYYPFGTSJXNS-UHFFFAOYSA-N 0.000 description 1
- 229950005967 mitozolomide Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 201000006462 myelodysplastic/myeloproliferative neoplasm Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 108010080874 neuroserpin Proteins 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 208000029211 papillomatosis Diseases 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 201000000389 pediatric ependymoma Diseases 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 201000003113 pineoblastoma Diseases 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229920002620 polyvinyl fluoride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 239000008262 pumice Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 190014017285 satraplatin Chemical compound 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 210000001768 subcellular fraction Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 229950002860 triplatin tetranitrate Drugs 0.000 description 1
- 190014017283 triplatin tetranitrate Chemical compound 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 208000018417 undifferentiated high grade pleomorphic sarcoma of bone Diseases 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 238000004832 voltammetry Methods 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7004—Stress
Definitions
- the present disclosure relates to methods of monitoring genotoxic stress in a test subject, specifically by detecting the expression level of microvesicle-associated H2AX from a biological sample.
- Agents that damage DNA or interfere with replication can be present in the environment, accidentally released, and/or intentionally administered. Exposure to these agents causes genotoxic stress in a wide variety of organisms. To assess the extent of damage/interference and whether such effects outweigh potential benefits arising from use of the agent, it is necessary to monitor, detect and/or measure genotoxic stress.
- Cancer is a leading cause of death worldwide. In 2004, it accounted for 7.4 million deaths (around 13% of all deaths). Deaths from cancer are expected to continue to rise, with a predicted 12 million deaths in 2030 (WHO, February 2009).
- Various treatments are available for cancer patients, such as chemotherapy, radiation, surgery, and drug therapy. Effective monitoring of cancer progression and treatment efficacy are critical to reducing the worldwide cancer burden, yet the development of robust and non-invasive methods and tools for monitoring disease progression and treatment efficacy remain major challenges in the field.
- the invention described herein meets the needs described above by providing methods of monitoring genotoxic stress in a test subject, specifically by detecting the expression level of microvesicle-associated H2AX in a biological sample.
- the H2AX to be detected may either be unphosphorylated or phosphorylated.
- the phosphorylated H2AX is ⁇ H2AX.
- the genotoxic stress is due to environmental contamination or radiation exposure. In other embodiments, the genotoxic stress is due to cancer treatment, such as administration of an anti-cancer agent or exposure to radiation.
- methods described herein include methods of monitoring genotoxic stress due to cancer treatment in a test subject by detecting the expression level of microvesicle-associated H2AX in a test subject, and monitoring the cancer treatment in the subject based on the expression level of the microvesicle-associated H2AX. In some embodiments, detecting the expression level of microvesicle-associated H2AX in a biological sample from the test subject occurs at a plurality of time points following administration of the cancer treatment.
- the cancer treatment includes administration of an anti-cancer agent such as a platinum analogue, a tetrazine, an anti-metabolite, a plant alkaloid or terpenoid, a cytotoxic antibiotic, a DNA alkylating agent (e.g., temozolomide), or a type I topoisomerase inhibitor (e.g., indenoisoquinoline).
- an anti-cancer agent such as a platinum analogue, a tetrazine, an anti-metabolite, a plant alkaloid or terpenoid, a cytotoxic antibiotic, a DNA alkylating agent (e.g., temozolomide), or a type I topoisomerase inhibitor (e.g., indenoisoquinoline).
- an anti-cancer agent such as a platinum analogue, a tetrazine, an anti-metabolite, a plant alkaloid or terpenoid, a cytotoxic antibiotic,
- monitoring the genotoxic stress involves comparing the expression level of H2AX in the biological sample from the test subject with the expression level of H2AX in a biological sample from a control subject that is not given the cancer treatment.
- a higher level of expression of H2AX in the biological sample from the test subject compared to the level of expression of H2AX in the biological sample from the control subject may indicate that the cancer treatment is inhibiting replication of DNA in cancer cells in the test subject.
- monitoring the genotoxic stress involves evaluating the efficacy of the cancer treatment.
- evaluating the efficacy of the cancer treatment in the test subject involves comparing the expression level of H2AX in the biological sample from the test subject with the expression level of H2AX in biological samples from a plurality of control subjects.
- the plurality of control subjects have the same type of cancer as the test subject and are administered the same cancer treatment as the test subject.
- the cancer treatment has a different level of treatment efficacy in each of the plurality of control subjects.
- a step is included for deriving a score from the comparison of the expression level of H2AX in the biological sample from the test subject with the expression level of H2AX in the biological samples from the plurality of control subjects, where the score indicates a level of similarity between the expression level of H2AX in the biological sample from the test subject and the expression level of H2AX in the biological samples from the plurality of control subjects.
- determining the level of efficacy of the cancer treatment in the test subject is based on the above mentioned score.
- the score used in determining the efficacy of the cancer treatment in the test subject is a correlation coefficient.
- the cancer in the above embodiments is a solid tumor.
- the cancer is pancreatic, ovarian, adenocarcinoma, prostate, breast, brain, head, neck, cervical, or lymphoma cancers.
- the brain cancer can be glioblastoma multiforme (WHO grade III and IV) or lower grade malignancies including, for example, anaplastic astrocytoma, oligoastrocytoma, oligodendrogliomas; ependymoma, medulloblastoma, meningioma, pineal tumors, or pituitary tumors.
- the biological sample in the above embodiments is plasma, serum, cerebrospinal fluid, urine, tears, milk, lymph fluid, synovial fluid, bronchoalveolar lavage, amniotic fluid, saliva, ocular fluid, ascites, and respiratory droplets.
- detecting the expression level of H2AX involves detecting binding of H2AX to an H2AX-specific antibody.
- the antibody is covalently bound to a bead.
- detecting binding of H2AX to an H2AX-specific antibody involves detecting fluorescence.
- detecting the expression level of microvesicle-associated H2AX involves the use of ELISA, flow cytometry, or liquid chromatography-mass spectrometry.
- isolating microvesicles from the biological sample prior to detecting the expression level of H2AX involves contacting the biological sample with a cancer-derived microvesicle-specific reagent where the biological sample includes microvesicles and the reagent binds to the microvesicles, contacting the microvesicles with a tissue-specific reagent, and isolating the microvesicles derived from the tissue.
- Certain aspects of the present disclosure relate to methods of monitoring genotoxic stress in a test subject by detecting the expression level of microvesicle-associated histone proteins in a biological sample from the test subject, and monitoring genotoxic stress in the subject based on the expression level of the microvesicle-associated histone protein.
- FIG. 1 illustrates a Western gel blot analysis of U87 brain tumor cell-shed microvesicle-derived total protein content from various microvesicle samples as a function of time or exposure to chemotherapeutic agent temozolomide (TMZ).
- TTZ chemotherapeutic agent temozolomide
- FIG. 2 A illustrates a Western blot analysis of ⁇ H2AX protein present in the various microvesicle samples.
- FIG. 2 B illustrates a Western blot analysis of H2AX protein present in the various microvesicle samples.
- FIG. 3 A illustrates a Western blot analysis of ⁇ H2AX protein present in various subcellular compartment samples from cells of the U87 tumor colony.
- FIG. 3 B illustrates a Western blot analysis of H2AX protein present in various subcellular compartment samples.
- FIG. 3 C illustrates a legend of the subcellular compartments analyzed in the blot and their respective labels.
- FIG. 4 illustrates a Western blot analysis of H2AX, ⁇ H2AX, and pan-Histone proteins present in microvesicle preparations from U87, Hela, and HEK293T cells under various conditions.
- the present disclosure relates to methods of monitoring genotoxic stress in a test subject, specifically by detecting the expression level of microvesicle-associated H2AX, either unphosphorylated or in its phosphorylated form (e.g., ⁇ H2AX), in a biological sample.
- microvesicle-associated H2AX either unphosphorylated or in its phosphorylated form (e.g., ⁇ H2AX)
- Histones are proteins which package DNA into nucleosomes, the repeating units that make up chromatin.
- Histone H2A is one of the five types of histone proteins.
- the variant histone H2AX has a C terminal tail that is used for DNA repair.
- H2AX and ⁇ H2AX are markers for genotoxic stress due to the role that histones play in packaging DNA into nucleosomes. Furthermore, phosphorylation of histone H2AX to ⁇ H2AX (ser 139) is a robust early indicator of DNA damage such as double stranded breaks (DSBs).
- the present disclosure includes the discovery of a non-invasive method for monitoring genotoxic stress in a test subject by detecting the expression level of H2AX associated with microvesicles.
- Genotoxic stress in a test subject can be induced by a variety of circumstances, for example, accidental exposure of subjects to genotoxins (e.g., environmental contamination) or radiation, hostile exposure to genotoxins or radiation, and cancer treatment designed to slow or stop the growth of rapidly dividing cancer cells. It should be understood by one of skill in the art that the embodiments described herein with respect to methods for monitoring genotoxic stress due to cancer treatment are also embodiments of methods for monitoring genotoxic stress induced by other circumstances.
- H2AX refers to a gamma-phosphorylated H2AX protein (i.e., phosphorylated on Serine 137). H2AX is a variant of the histone protein H2A.
- H2AX refers to all derivatives of H2AX, including both the unphosphorylated and phosphorylated forms of the protein.
- the phosphorylated residue of the derivative may be Serine 137 or another residue.
- Monitoring refers to the act of observing. Monitoring a treatment may include observing a change in the expression level of a protein in an individual receiving that treatment over time.
- Microvesicle refers to any small vesicle released from any cell type.
- Microvesicles include, for example, endosome-derived exosomes, plasma membrane-derived shedding vesicles, apoptotic bodies, prostasomes, P2 and P4 particles, and outer membrane vesicles (OMVs).
- Shedding vesicles may be referred to as ectosomes, microparticles, shedding bodies, exovesicles, or secretory vesicles.
- Protasomes may be referred to as aposomes or seminosomes.
- P2 and P4 particles may be referred to as prominosomes.
- microvesicle-associated protein refers to any protein that has been contained within or located on the surface of a microvesicle. “Microvesicle-associated protein” can refer to such a protein while the protein is still associated with a microvesicle or after the protein is no longer associated with a microvesicle. In preferred embodiments, the microvesicle-associated protein is ⁇ H2AX.
- Described herein are methods of monitoring, detecting or measuring genotoxic stress due to cancer treatment, specifically by detecting the expression level of microvesicle-associated H2AX in a biological sample from a test subject.
- the cancer treatment may be any treatment which is used to slow or stop the progression of the cancer. Such treatments may work via a wide variety of mechanisms ranging from alkylating DNA to interfering with other aspects of the DNA replication process. Exemplary methods include treatment with anti-cancer agents and/or exposure to radiation.
- Anti-cancer agents include classical DNA alkylating agents such as temozolomide; nitrogen mustard; cyclophosphamide; mechlorethamine or mustine (HN2) (trade name Mustardgen); uramustine or uracil mustard; melphalan; chlorambucil; ifosfamide; nitrosoureas such as carmustine, lomustine and streptozocin; alkyl sulfonates such as busulfan; and Thiotepa.
- DNA alkylating agents such as temozolomide; nitrogen mustard; cyclophosphamide; mechlorethamine or mustine (HN2) (trade name Mustardgen); uramustine or uracil mustard; melphalan; chlorambucil; ifosfamide; nitrosoureas such as carmustine, lomustine and streptozocin; alkyl sulfonates such as busulfan; and Thiotepa.
- Alkylating-like drugs include the platinum-based chemotherapeutic drugs (termed platinum analogues) such as cisplatin, carboplatin, nedaplatin, oxaliplatin, satraplatin, and triplatin tetranitrate,
- the anti-cancer agent is a tetrazine, e.g., dacarbazine, mitozolomide, or temozolomide.
- anti-cancer agents include anti-metabolites which mimic purines (e.g., azathioprine, mercaptopurine) or pyrimidines and become incorporated into the DNA.
- purines e.g., azathioprine, mercaptopurine
- pyrimidines e.g., pyrimidines
- Additional exemplary anti-cancer agents are the plant alkaloids and terpenoids, which block cell division by preventing microtubule function.
- the main examples of such anti-cancer agents are Vinca alkaloids and taxanes.
- the Vinca alkaloids include, without limitation, vincristine, vinblastine, vinorelbine, and vindesine.
- the taxanes include, without limitation, paclitaxel, originally known as Taxol and docetaxel. a semi-synthetic analogue of paclitaxel.
- Anti-cancer agents also include topoisomerase inhibitors.
- Type I topoisomerase inhibitors include the camptothecins, irinotecan and topotecan.
- Type II inhibitors include amsacrine, etoposide, etoposide phosphate, and teniposide. These are semisynthetic derivatives of epipodophyllotoxins.
- Anti-cancer agents also include cytotoxic antibiotics, for example, actinomycin, anthracyclines (e.g., doxorubicin, daunorubicin, vahrubicin, idarubicin, epirubicin), bleomycin, plicamycin, and mitomycin.
- actinomycin anthracyclines (e.g., doxorubicin, daunorubicin, vahrubicin, idarubicin, epirubicin), bleomycin, plicamycin, and mitomycin.
- the anti-cancer agents are DNA alkylating agents, such as temozolomide, or topoisomerase inhibitors, such as indenoisoquinoline,
- the indenoisoquinoline may include, without limitation, National Cancer Institute lead compounds NSC 706744, NSC 725776 (Indimitecan), NSC 724998 (Indotecan), as well as 6-Ethyl-5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline, 5,6-Dihydro-5,11-diketo-6-propyl-11H-indeno[1,2-c]isoquinoline, 6-Cyclopropyl-5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline, 5,6-Dihydro-5,11-diketo-6(methoxycarbonylmethyl)-11H-indeno[1,2-c]isoquinoline, 5,6-Dihydro-6-(4-hydroxy-1-butyl)-5,11-diketollH-indeno[1,2-c]isoquinoline, 5,6-Dihydroxy-6-(5-
- detecting the expression level of microvesicle-associated ⁇ H2AX in a biological sample from the test subject occurs at a plurality of time points following administration of the cancer treatment.
- detecting the expression level of microvesicle-associated H2AX in a biological sample from the test subject following cancer treatment occurs at least after one day, at least after 3 days, at least after 4 days, at least after 5 days, at least after 6 days, at least after 7 days, at least after 8 days, at least after 10 days, at least after 12 days, at least after 14 days, at least after 16 days, at least after 18 days, at least after 20 days, at least after 21 days, at least after 25 days, at least after 30 days, at least after 2 months, at least after 4 months, at least after 6 months, at least after 8 months, at least or after 12 months.
- monitoring the cancer treatment involves comparing the expression level of H2AX in the biological sample from the test subject with the expression level of H2AX in a biological sample from a control subject that is not given the cancer treatment.
- a higher level of expression of H2AX in the biological sample from the test subject compared to the level of expression of H2AX in the biological sample from the control subject indicates that the cancer treatment is inducing genotoxic stress in the test subject.
- an expression level is said to be increased or decreased relative to a second expression level if the difference between the two expression levels is statistically significant. The difference between two levels is considered to be statistically significant if it was unlikely to have occurred by chance. Statistical significance may be measured by any means known in the art, such as, for example, Fisherian statistical hypothesis testing or the Neyman-Pearson lemma.
- monitoring the cancer treatment includes evaluating the efficacy of the cancer treatment in the test subject.
- Evaluating the efficacy may include methods of comparing the expression level of H2AX in the biological sample from the test subject with the expression level of H2AX in biological samples from a plurality of control subjects.
- Evaluating the efficacy may further include methods for assigning a score to the test subject based on expression levels of H2AX in test subjects compared to control subjects.
- each of the plurality of control subjects has the same type of cancer as the test subject and is administered the same cancer treatment as the test subject.
- the cancer treatment has a different level of treatment efficacy in each of the plurality of control subjects.
- a step is included for deriving a score from the comparison of the expression level of H2AX in the biological sample from the test subject with the expression level of H2AX in the biological samples from the plurality of control subjects, where the score indicates a level of similarity between the expression level of H2AX in the biological sample from the test subject and the expression level of H2AX in the biological samples from the plurality of control subjects.
- determining the level of efficacy of the cancer treatment in the test subject is based on the above mentioned score.
- the score may be derived by any methods known to one of skill in the art. In certain embodiments, the score may simply be a measure of the difference in expression levels. In preferred embodiments, the score is a correlation coefficient. A correlation coefficient describes the similarity between two expression patterns. Expression levels may be considered similar if the correlation coefficient is greater than or equal to 0.5. In preferred embodiments, for expression levels to be considered significantly similar, the correlation coefficient should be greater than 0.6, 0.7, 0.8, 0.9, or 0.95. In other embodiments, the score is generated by other statistical methods which produce a measure of mutual information to describe the similarity between two expression patterns. Expression levels may be considered similar if the normalized mutual information value is greater than or equal to 0.7. In preferred embodiments, for the expression levels to be considered significantly similar, the normalized mutual information value should be greater than 0.8, 0.9, or 0.95.
- the test subject can be said to have or to be likely to have the same efficacy of cancer treatment as that of the plurality of control subjects.
- the cancer treatment can be said to be or likely to be efficacious.
- the described methods may be applied to treatment of any type of cancer including, without limitation, adult acute lymphoblastic leukemia, childhood acute lymphoblastic leukemia, adult acute myeloid leukemia, childhood acute myeloid leukemia, adrenocortical carcinoma, childhood adrenocortical carcinoma, aids-related cancers, aids-related lymphoma, anal cancer, appendix cancer, basal cell carcinoma, extrahepatic bile duct cancer, bladder cancer, childhood bladder cancer, bone cancer, osteosarcoma and malignant fibrous histiocytoma, childhood brain stem glioma, adult brain tumor, childhood central nervous system atypical teratoid/rhabdoid tumor, childhood central nervous system embryonal tumors, childhood astrocytomas, childhood pineal parenchymal tumors of intermediate differentiation, childhood supratentorial primitive neuroectodermal tumors and pineoblastoma, childhood brain and spinal cord tumors, breast cancer, childhood breast cancer, male breast cancer, childhood bronchial
- the brain cancer can be glioblastoma multiforme (WHO grade III and IV) or lower grade malignancies including, for example, anaplastic astrocytoma, oligoastrocytoma, oligodendrogliomas; ependymoma, medulloblastoma, meningioma, pineal tumors, or pituitary tumors.
- WHO grade III and IV glioblastoma multiforme
- lower grade malignancies including, for example, anaplastic astrocytoma, oligoastrocytoma, oligodendrogliomas; ependymoma, medulloblastoma, meningioma, pineal tumors, or pituitary tumors.
- treatment is for cancer that is a solid tumor.
- the treatment is for a blood cancer such as leukemia, lymphoma, and myeloma.
- the cancer is selected from pancreatic, ovarian, adenocarcinoma, brain, prostate, breast, head, neck, or lymphoma cancers.
- the cancer is a glioma, such as glioblastoma multiforme.
- Methods of the present disclosure include a step of detecting the expression level of microvesicle-associated H2AX, either when associated with the microvesicle or subsequent to dissociation from the microvesicle.
- detecting the expression level of H2AX involves detecting binding of H2AX to an H2AX-specific antibody, e.g., ELISA.
- the antibody is covalently bound to a bead.
- detecting binding of H2AX to an H2AX-specific antibody involves detecting fluorescence.
- the level of H2AX is measured directly, using for example, flow cytometry or a liquid chromatography-mass spectrometry.
- the method involves isolating cancer-derived microvesicles from the biological sample prior to detecting the expression level of H2AX.
- isolating microvesicles from the biological sample prior to detecting the expression level of H2AX involves contacting the biological sample with a cancer-derived microvesicle-specific reagent where the biological sample includes microvesicles and the reagent binds to the microvesicles, contacting the microvesicles with a tissue-specific reagent, and isolating the microvesicles derived from the tissue.
- the expression level of H2AX may include a relative or absolute amount of a protein in a sample, or it may simply refer to the presence or absence of a protein in a sample.
- the expression level of the microvesicle-associated H2AX may be detected by any methods known to one of skill in the art (see, for example: Coligan et al, Unit 9 , Current Protocols in Immunology , Wiley Interscience, 1994), which include, without limitation: immunohistochemistry ( Microscopy, Immunohistochemistry and Antigen Retrieval Methods for Light and Electron Microscopy , M. A.
- the protein is dissociated from microvesicles.
- the microvesicles are lysed, and the proteins in the microvesicles are extracted, precipitated, and reconstituted for analysis.
- the microvesicles are kept intact so that the protein remains associated, and the microvesicles are attached to a column, resin, or bead.
- the reconstituted protein or the microvesicles attached to a column, resin, or bead are used in the detection step.
- the reconstituted protein or the microvesicles attached to a column, resin, or bead are contacted with an antibody specific to the H2AX biomarker.
- detecting the expression level includes detecting binding of H2AX to an antibody specific to this protein.
- Antibodies may be monoclonal or polyclonal, and they may be obtained from a commercial source or generated for use in the methods described herein. Methods for producing and evaluating antibodies are well known in the art, see, e.g., Coligan, (1997) Current Protocols in Immunology , John Wiley & Sons, Inc; and Harlow and Lane (1989) Antibodies: A Laboratory Manual , Cold Spring Harbor Press, NY (“Harlow and Lane”).
- the antibody may be covalently bound to a bead or fixed on a solid surface, such as glass, plastic, or silicon chip.
- the biological sample is contacted with an antibody specific to H2AX. Any H2AX protein present in the sample will bind to the H2AX antibody.
- the mixture is washed, and the antibody-protein biomarker complexes can be detected.
- H2AX is detected after the protein binds to an anti-H2AX antibody that is bound to a bead.
- This detection can be achieved by contacting the washed antibody-protein biomarker complexes with a detection reagent.
- This detection reagent may be, for example, a secondary antibody which is labeled with a detectable label.
- detectable labels include magnetic beads (e.g., DYNABEADSTM), fluorescent dyes, radiolabels, enzymes (e.g., horseradish peroxide, alkaline phosphatase, and others commonly used in ELISA), and colorimetric labels such as colloidal gold, colored glass, or plastic beads.
- H2AX is detected after the protein binds to an anti-H2AX antibody and includes detection of fluorescence.
- Methods for measuring the amount of, or presence of, antibody-marker complexes include, for example, detection of fluorescence, luminescence, chemiluminescence, absorbance, reflectance, transmittance, birefringence, or refractive index (e.g., surface plasmon resonance, ellipsometry, a resonant mirror method, a grating coupler waveguide method, or interferometry).
- Optical methods include microscopy (both confocal and non-confocal), imaging methods, and non-imaging methods.
- Electrochemical methods include voltametry and amperometry methods.
- Radio frequency methods include multipolar resonance spectroscopy. Methods for performing these assays are readily known in the art.
- Useful assays include, for example, an enzyme immune assay (EIA) such as enzyme-linked immunosorbent assay (ELISA), a radioimmune assay (RIA), a Western blot assay, or a slot blot assay.
- EIA enzyme immune assay
- ELISA enzyme-linked immunosorbent assay
- RIA radioimmune assay
- Western blot assay or a slot blot assay.
- H2AX is detected after the protein binds to an anti-H2AX antibody and includes detection of fluorescence.
- incubation and/or washing steps may be required after each combination of reagents. Incubation steps can vary from about 5 seconds to several hours, preferably from about 5 minutes to about 24 hours. However, the incubation time will depend upon the assay format, marker, volume of solution, concentrations, and the like. Usually the assays will be carried out at ambient temperature, although they can be conducted over a range of temperatures, such as 10° C. to 40° C.
- Immunoassays can be used to determine the presence or absence of a marker in a sample as well as the quantity of a marker in a sample.
- the amount of an H2AX/anti-H2AX complex can be determined by comparing to a standard.
- a standard can be, e.g., a known compound or another protein known to be present in a sample.
- the test amount of H2AX need not be measured in absolute units, as long as the unit of measurement can be compared to a control.
- the methods include detecting the expression level of microvesicle-associated H2AX in a biological sample from the test subject.
- the biological sample may be any sample from the body of the test subject that contains microvesicles.
- the biological sample is a bodily fluid.
- a “bodily fluid” refers to a sample of fluid isolated from anywhere in the body of the test subject, preferably a peripheral location, including but not limited to, for example, blood, plasma, serum, urine, sputum, spinal fluid, pleural fluid, nipple aspirates, lymph fluid, respiratory droplets, intestinal, and genitourinary tracts, tears, saliva, breast milk, fluid from the lymphatic system, semen, cerebrospinal fluid, intra-organ system fluid, ascitic fluid, tumor cyst fluid, synovial fluid, amniotic fluid, ocular fluid, ascites, bronchoalveolar lavage, and combinations thereof.
- the biological sample is blood. If the sample is blood, is it preferably centrifuged to remove cellular material and debris such that a plasma fraction is generated.
- the biological sample includes, but is not limited to, plasma, serum, cerebrospinal fluid, urine, tears, milk, lymph fluid, synovial fluid, bronchoalveolar lavage, amniotic fluid, saliva, ocular fluid, ascites, and respiratory droplets.
- the H2AX detected in the methods are associated with microvesicles present in the biological sample.
- the microvesicles may be derived from endosomes (exosomes) or from the plasma membrane (shedding vesicles).
- the microvesicles may also be, for example, apoptotic bodies, prostasomes, P2 and P4 particles, or outer membrane vesicles (OMVs).
- OMVs outer membrane vesicles
- the 1H2AX associated with the microvesicles may be membrane proteins or cytosolic proteins.
- the methods may include a step of isolating microvesicles from the biological sample prior to detecting the expression level of H2AX.
- Various different populations of microvesicles may be isolated. For example, when the methods relate to detection of the expression level of H2AX expressed by all tissues, the entire population of microvesicles is isolated. When the methods relate to detection of the expression level of expressed by multiple tissues, a specific sub-population of microvesicles derived from these tissues is isolated. When the methods relate to detection of the expression level of protein biomarkers expressed by a single tissue, microvesicles derived from that specific tissue are isolated. In preferred embodiments, microvesicles from various tissues are isolated by contacting microvesicles with a tissue-specific reagent.
- microvesicles may be isolated according to any methods known to one of skill in the art (see, for example, Cocucci et al., Traffic 8, 2007: 742-757; Simpson et al., Proteomics 8, 2008: 4083-4099).
- isolating microvesicles involves centrifugation.
- serial centrifugation may be used to remove cells and debris, and microvesicles may be pelleted using sedimentation at 60-100,000 ⁇ g for 1 hour or longer. Additional methods of differential centrifugation are described in Raposo et al., J Exp Med 183, 1996: 1161-72.
- microvesicles may be isolated by passing the biological sample through a filter having an average pore diameter of between 0.01 m and about 0.15 ⁇ m.
- Linear sucrose gradients (2.0-0.25 M sucrose), or a combination of ultrafiltration (500 K membrane) and ultracentrifugation into a 30% sucrose/deuterium oxide (98%) cushion (density, 1.210 g/cm 3 ) may also be used.
- Various methods for the isolation of microvesicles can be found, for example, in U.S. Pat. Nos. 6,899,863, 6,812,023, Taylor and Gercel-Taylor, Gynecol Oncol 110, 2008: 13-21, Cheruvanky et al., Am J Physiol Renal Physiol 292, 2007: F1657-61, and Nagrath et al., Nature 450, 2007: 1235-9.
- isolation of microvesicles is accomplished using affinity capture methods.
- affinity methods are immunoaffinity methods, but in certain embodiments, such methods employ other reagents which bind specifically to H2AX. Such methods can be a step in other methods prior to detection of H2AX described above.
- the entire population of microvesicles may be isolated by contacting biological samples containing microvesicles with a reagent specific to a protein commonly found on the surface of all microvesicles regardless of origin (i.e., microvesicle-specific reagents).
- the reagents are specific to the following proteins: membrane adhesion proteins (integrins), membrane transport/trafficking proteins (annexins and Rab proteins, such as Rab guanosine triphosphatase), cytoskeletal components (actin, tubulin, ERM proteins, lysosomal markers, and tetraspanin proteins, such as CD9, CD63, CD81, and CD82), antigen presenting proteins (HLA class I and II), death receptors, cytokines and cognate receptors (TNF, TNFR1, and TGF- ⁇ ), iron transport proteins, enzymes (enolase), cytosolic proteins (Hsc73 and Hsc90), subunits of trimeric G proteins, Tsg101, milk-fat globule (MFG)-E8, lactadherin, MHC class I molecules, heat shock proteins (Hsp70 and Hsp90), drug transporter proteins, or signal transduction proteins.
- membrane adhesion proteins integrins
- reagents are specific to microvesicles from specific cell types such as class II MHC and co-stimulatory molecules (CD86) from antigen-presenting cells, von Willebrand factor or CD41a (GPIIb) from platelets, TCR from T-cells, or perforin or granzyme from cytotoxic T cells (Caby el al., Inter Immunol 17(7); 879-887; 2005). Reagents specific for lipids on the surface of microvesicles may also be used.
- cell types such as class II MHC and co-stimulatory molecules (CD86) from antigen-presenting cells, von Willebrand factor or CD41a (GPIIb) from platelets, TCR from T-cells, or perforin or granzyme from cytotoxic T cells (Caby el al., Inter Immunol 17(7); 879-887; 2005).
- Reagents specific for lipids on the surface of microvesicles may also be used.
- the immunoaffinity capture includes use of an anti-phosphatidylserine antibody which binds to microvesicles having phosphatidylserine molecules with the polar side of the molecule exposed on its outer surface.
- the antibody is preferably monoclonal, but can also be polyclonal.
- the first step isolates a specific sub-population of microvesicles, for example, those derived from endosomes or those derived from plasma membrane using antibodies specific to these sub-populations.
- microvesicles may first be contacted with a reagent which binds specifically to microvesicles which are derived from a cancerous cell (i.e., cancer-derived microvesicle-specific reagent).
- a reagent which binds specifically to microvesicles which are derived from a cancerous cell
- Such a reagent may be one that binds only to microvesicles derived from cancerous cells or one that binds to any composition, such as a microvesicle, which displays certain cancer-specific proteins on its surface. If the reagent is the latter, the methods described herein will also include a step for isolating microvesicles or distinguishing them from other compositions found in the samples.
- Exemplary cancer-derived microvesicle-specific reagents include antibodies specific to tumor cell surface proteins or tumor antigen proteins.
- these proteins include tumor surface antigens, tumor invasion-related proteins, angiogenesis proteins, immune-suppressing cytokines, integrin proteins, and proteases.
- these proteins include cancer-specific cell-surface proteins such as those listed below in Table 1.
- the cancer-derived microvesicle-specific reagent is a reagent specific for phosphatidylserine, EGFRvIII, IDH1, PDGFRalpha, VEGFR, or ⁇ v / ⁇ III integrin.
- FIG. 1 Cancer-Specific Markers Cancer-Specific Markers APC C18orf8 C6orf138 CD44 CDH1 CDH11 CDH6 CDKN2A CDON CEP76 CTNNA1 CTNNB1 DHH FAT FGF9
- FIGF FKBP8 FLT1 FLT4 FN1 FXYD5 GLI1 GLI2 GLI3 GSK3B HHAT HHIP IFT52 IHH ITGA7 ITGB3 KDR KITLG LAMR1 MCAM MGAT5 MMP10 MMP11 MMP13 MMP2 MMP3 MMP7 MMP9 MTSS1 NF1 NF2 NPC1 NPC1L1 NRP1 NRP2 OTX2 PDGFC PGF PNN PTCH1 PTCH2 PTCHD1 PTCHD2 PTCHD3 RPSA SHH SIAH1 SMO SUFU SYK TGFB1 TIMP2 TIMP3 TIMP4 VEGF VEGFA VEGFB VEGFC
- the cancer-derived microvesicle-specific reagent only binds to cancer-derived microvesicles derived from certain tissue types.
- the cancer-derived microvesicle-specific reagent is also a tissue-specific reagent.
- the microvesicles Before, subsequent to, or at the same time as capture with a first microvesicle-specific or cancer-derived microvesicle-specific reagent, the microvesicles, either in isolated form or found in the biological sample, can be contacted with a tissue-specific reagent to isolate microvesicles derived from a specific tissue.
- tissues of interest include brain, adrenal gland, endocrine gland, pituitary, hypothalamus, parathyroid, uterus, heart, blood vessel, stomach, trachea, pharynx, gums, hair, scalp, subcutaneous tissue, Fallopian tube, reproductive tract, urethra, skin, bone, stem cell, umbilical cord, placenta, lymphocyte, monocyte, macrophage, formed blood cell, smooth muscle, skeletal muscle, connective tissue, spinal cord, kidney, bladder, anus, bone, breast, prostate, lung, cervix, colon, rectum, uterus, esophagus, skin, liver, pharynx, mouth, neck, ovary, pancreas, lung, eye, intestine, mouth, thyroid, GI tract, and endometrium.
- organelles of interest include plasma membrane, peroxisome, smooth ER, rough ER, lysosome, mitochondria, and nucleus.
- each step is performed using multiple microvesicle-specific, cancer-derived microvesicle-specific, or tissue-specific reagents.
- an anti-tenascin-C specific antibody is used to isolate microvesicles from brain tissue.
- microvesicles derived from certain tissues are isolated using antibodies to tissue markers known to those of skill in the art.
- markers for brain tissue include VLP-1, synaptosomal-associated protein, GAD67, myelin-associated oligodendrocyte basic protein, synaptotagmin I, tubulin ⁇ 4, zygin, glycine receptor ⁇ , protein 1 kinase C and casein kinase substrate in neurons 1, internexin neuronal intermediate filament protein a, neuroserpin, synaptobrevin 2, or neurogranin (Laterza et al.; Clin Chem 52:9; 1713-21; 2006).
- the entire population of microvesicles is contacted with an reagent which binds to microvesicles derived from multiple tissue types rather than one that binds microvesicles derived from a specific tissue.
- the method includes contacting a biological sample with an reagent specific for microvesicles, preferably a reagent specific for phosphatidylserine, wherein the biological sample includes microvesicles and the reagent binds to microvesicles; contacting the microvesicles with a tissue-specific reagent and then isolating the microvesicles derived from the tissue(s).
- an reagent specific for microvesicles preferably a reagent specific for phosphatidylserine
- methods for isolating microvesicles derived from brain cancer tissue from blood include the steps of providing blood; providing plasma by centrifuging the blood; contacting plasma with an anti-phosphatidylserine antibody in a physiological buffer, wherein the anti-phosphatidylserine antibody binds to microvesicles; isolating microvesicles bound by the anti-phosphatidylserine antibody; contacting the microvesicles with an anti-tenascin antibody; and isolating the microvesicles derived from brain cancer tissue.
- the plasma is contacted with an anti-phosphatidylserine antibody for about 60 minutes and the microvesicles are isolated by changing the ionic strength of the physiological buffer.
- a biological sample with an microvesicle-specific reagent or cancer-derived microvesicle-specific reagent and contacting the microvesicles with a tissue-specific reagent may occur in a single step. Under such circumstances, the reagents may be coupled to the same solid support. Alternatively, the steps are performed sequentially.
- the biological sample is first contacted with a microvesicle-specific reagent/cancer-derived microvesicle-specific reagent and then contacted with a tissue-specific reagent, sometimes with an intervening step of isolating the microvesicles bound by a microvesicle-specific/cancer-derived microvesicle-specific reagent.
- the steps may also be reversed, such that biological sample is first contacted with a tissue-specific reagent and then a microvesicle-specific/cancer-derived microvesicle-specific reagent, sometimes with an intervening step of isolating a fraction bound by the tissue-specific reagent.
- the biological sample and the reagents are incubated together in a suitable buffer at physiological pH at a suitable temperature (e.g., about 4-37° C.), for a suitable time period (e.g., about 60 minutes to overnight) to allow the binding to occur.
- a suitable buffer at physiological pH at a suitable temperature (e.g., about 4-37° C.), for a suitable time period (e.g., about 60 minutes to overnight) to allow the binding to occur.
- microvesicles are isolated using standard methods known to those of skill in the art. For example, if the microvesicles are bound to an immunoaffinity resin, the resin is washed with physiological buffers, such as Tris-Acetate pH 7.6 to remove other unbound components of the biological sample and then eluted by changing the ionic strength of the buffer for the resin, for example, by gradually increasing the concentration of a salt, such as NaCl, CaCl 2 , KCl, MgCl 2 , or similar salts that cause the reagent to release the bound microvesicles. Sepharose 2B columns may also be used for size exclusion methodologies of isolating microvesicles (Taylor et al., 2012).
- physiological buffers such as Tris-Acetate pH 7.6
- a salt such as NaCl, CaCl 2 , KCl, MgCl 2 , or similar salts that cause the reagent to release the bound microvesicles.
- a solid support for purposes of the present disclosure, can be any material that is an insoluble matrix and can have a rigid or semi-rigid surface to an reagent can be linked or attached.
- Exemplary solid supports include, but are not limited to, substrates such as nitrocellulose, polyvinylchloride; polypropylene, polystyrene, latex, polycarbonate, nylon, dextran, chitin, sand, silica, pumice, agarose, cellulose, glass, metal, polyacrylamide, silicon, rubber, polysaccharides, polyvinyl fluoride, diazotized paper, activated beads, magnetically responsive beads, and any materials commonly used for solid phase synthesis, affinity separations, purifications, hybridization reactions, immunoassays and other such applications.
- the support can be particulate or can be in the form of a continuous surface and includes membranes, mesh, plates, pellets, slides, disks, capillaries, hollow fibers, needles, pins, chips, solid fibers, gels (e.g. silica gels) and beads, (e.g., pore-glass beads, silica gels, polystyrene beads optionally cross-linked with divinylbenzene, grafted co-poly beads, polyacrylamide beads, latex beads, dimethylacrylamide beads optionally crosslinked with N-N′-bis-acryloylethylenediamine, iron oxide magnetic beads, and glass particles coated with a hydrophobic polymer.
- gels e.g. silica gels
- beads e.g., pore-glass beads, silica gels, polystyrene beads optionally cross-linked with divinylbenzene, grafted co-poly beads, polyacrylamide beads, latex beads, dimethylacrylamide beads optionally crosslinked with
- the solid support is a bead or resin in a column configuration.
- the method includes providing a column, applying a biological sample suspected of containing one or more of the microvesicles of interest to bind to resins in the column, washing the column, eluting the resins and analyzing the eluant for the presence of the microvesicles of interest.
- such methods can include loading the column with a predetermined amount of a biological sample suspected of containing the microvesicles of interest in either blood plasma or a physiological buffer; binding the microvesicles to the reagent on the column; loading the column with a wash solution, suspending the resin in the wash solution; removing the wash solution from the column; eluting the microvesicles in eluant; and analyzing the eluant for the presence of the microvesicles.
- the column configuration used in such methods allows for suspension of the resin beads, such as a mobile bead column or other resin during washing. It has been discovered that such a column configuration results in significantly lower levels of background and hence more sensitive levels of quantitation and overall yield of the desired target.
- the column used in such methods includes a lower end including an outflow opening; a lower porous support; a layer of resin on the lower porous support, the resin having specific affinity for all microvesicles or tissue-specific microvesicles; an upper porous support; and an upper end including an inflow opening; wherein the resin between the lower porous support and the upper porous support is structured and arranged to permit removal of the upper porous support from the column without substantial removal of resin.
- the resin is fixed between two semi-porous frits such that the resin beads may be suspended and such that the upper frit may be removed during washing of the resin to remove background compounds.
- the volume of the resin in the column can vary but is typically less than the total packed volume of the column between the lower porous support and the upper porous support.
- the volume of the resin in the column is no greater than 50%, more preferably no greater than 40%, even more preferably no greater than 30%, still more preferably no greater than 25%, and still more preferably no greater than 20% of the total packed volume of the column between the lower porous support and the upper porous support.
- Described herein are methods of monitoring genotoxic stress due to cancer treatment in a test subject, specifically by detecting the expression level of microvesicle-associated H2AX.
- methods include comparing the expression level of H2AX in the biological sample from the test subject with the expression level of H2AX in a biological sample from a control subject that is not given the cancer treatment.
- the expression levels from biological samples from the plurality of control subjects may be simultaneously obtained with the test subject expression levels or may constitute a set of numerical values stored on a computer or on computer readable medium.
- the control subjects are of the same sex and of a similar age as the test subject. Control subjects may also be of a similar racial background as the test subject.
- biological samples taken from the test subject and from the plurality of control subjects are of the same type, e.g., blood samples.
- Comparison of the expression levels of the one or more microvesicle-associated H2AX in biological samples from the test subject and from a plurality of control subjects may be performed manually or automatically by a computer program.
- the expression level of H2AX in the biological sample from the test subject may be compared individually to the expression level of the microvesicle-associated H2AX from biological samples in each control subject, or the expression level of microvesicle-associated H2AX in the biological sample from the test subject may be compared to an average of the expression levels from biological samples from the plurality of control subjects.
- the values for the expression levels of H2AX in biological samples from both the test subject and the plurality of control subjects may be transformed.
- the expression levels may be transformed by taking the logarithm of the value.
- the expression levels may be normalized by, for example, dividing by the median expression level among all of the samples.
- the expression level of microvesicle-associated H2AX in the biological sample from the test subject is increased relative to the expression level of the one or more microvesicle-associated H2AX in biological samples from a plurality of control subjects. In other embodiments, the expression level of microvesicle-associated H2AX in the biological sample from the test subject is decreased relative to the expression level of microvesicle-associated H2AX in biological samples from a plurality of control subjects.
- An entity may be, for example, a person, a group of people, an institution, or a business.
- the steps required to practice the method are practiced by one entity.
- a single entity may detect the expression levels of microvesicle-associated H2AX in a biological sample from the test subject and then monitor the cancer treatment or determine the efficacy of cancer treatment.
- This entity may be, for example, a doctor or a clinician.
- This entity may also be an institution, such as a hospital or a doctor's office, where all steps of the methods are performed by employees of the institution.
- a single entity may detect the expression levels of microvesicle-associated H2AX in a biological sample from the test subject and communicate the expression levels to a different entity that then monitors the cancer treatment or determines the efficacy of the cancer treatment.
- the single entity performing the steps of detecting and communicating may be, for example, a clinic or a lab technician.
- the steps required to practice the method may be performed by more than one entity.
- One entity may detect the expression levels of microvesicle-associated H2AX in a biological sample from the test subject, whereas a different entity may monitor the cancer treatment or determine the efficacy of the cancer treatment.
- a lab technician at a clinic may detect the expression levels of H2AX in a biological sample from the test subject, and a doctor at a hospital may determine the efficacy of the cancer treatment.
- a first entity may obtain expression levels of microvesicle-associated H2AX in a biological sample from the test subject from a second entity that detects the expression levels of microvesicle-associated H2AX in a biological sample from the test subject.
- the first entity may obtain the expression levels from the second entity directly or indirectly.
- the first entity may obtain a paper or electronic report of the expression levels directly from the second or different entity.
- the first entity may obtain an electronic report of the expression levels on a network to which the second entity has uploaded the report.
- the first entity may obtain the expression levels from a third entity that has prepared a report from the detections by the second entity.
- a first entity may detect the expression levels of microvesicle-associated H2AX in a biological sample from the test subject and communicate the expression levels to a second or different entity that then monitors the cancer treatment or determines the efficacy of the cancer treatment.
- the first entity may communicate the expression levels to the second entity directly or indirectly.
- the first entity may prepare a report with the expression levels and give the report to the second entity manually or electronically.
- the first entity may upload the expression levels to a network from which the second entity can obtain the levels.
- the first entity may communicate the expression levels to a third entity that prepares a report for use by the second entity.
- Methods described herein may be useful for clinical trials involving cancer.
- the steps required to achieve the objects of the invention will be practiced by more than one entity.
- multiple entities in different locations such as clinics in different cities, may detect the expression levels of the one or more microvesicle-associated proteins in a biological sample from the test subject and communicate the expression levels to a different entity, such as a group of doctors directing the clinical trial, who then determine the efficacy of the cancer treatment.
- the multiple entities may use a third entity that prepares and communicates reports of the expression levels to the different entity that determines the efficacy of the cancer treatment.
- Clinical trials involving the described methods may be useful for evaluating effectiveness of new drugs and treatments for cancer or for evaluating the effects of various clinical parameters on cancer and its progression.
- reagents and kits thereof for practicing one or more of the above-described methods.
- the subject reagents and kits thereof may vary greatly.
- Reagents of interest include reagents specifically designed for use in detection of the above-described expression levels of microvesicle-associated H2AX.
- One type of such reagent is an array or kit of antibodies that bind to a biomarker cluster of interest.
- array formats are known in the art, with a wide variety of different probe structures, substrate compositions, and attachment technologies.
- Representative array or kit compositions of interest include or consist of reagents for quantitation of at least 1 microvesicle-associated protein, such as H2AX.
- kits may further include a software package for statistical analysis of one or more phenotypes, and may include a reference database for calculating the probability of classification.
- the kit may include reagents employed in the various methods, such as devices for withdrawing and handling blood samples, second stage antibodies, ELISA reagents, tubes, spin columns, and the like.
- the subject kits will further include instructions for practicing the subject methods. These instructions may be present in the subject kits in a variety of forms, one or more of which may be present in the kit.
- One form in which these instructions may be present is as printed information on a suitable medium or substrate, e.g., a piece or pieces of paper on which the information is printed, in the packaging of the kit, in a package insert, etc.
- Yet another means would be a computer-readable medium, e.g., diskette, CD, etc., on which the information has been recorded.
- Yet another means that may be present is a website address which may be used via the internet to access the information at a removed site. Any convenient means may be present in the kits.
- microvesicle-derived unphosphorylated H2AX and microvesicle-derived ⁇ H2AX are markers of genotoxic stress in a cell.
- Treatment of U87 brain cancer cells with the DNA alkylating agent temozolomide (TMZ) induced increased abundance of H2AX and ⁇ H2AX proteins in microvesicles derived from the U87 cells.
- TMZ DNA alkylating agent temozolomide
- U87 MG (ATCC® HTB14TM) cell cultures represent glioblastoma multiforme (GBM).
- GBM glioblastoma multiforme
- An Integra CELLine Bioreactors Human, N.H. was seeded from T-75 cultures of U87 into the 15 ml lower chamber, separated by a 10 kDa MWCO filter from a 500 ml upper reservoir chamber. After growth was established in the lower chamber containing exosome free fetal bovine serum (Exo-FBS Systems Biosciences, Mountain View Calif.), supernatant samples were recovered on a weekly basis. Upper chambers of the bioreactors were replenished with normal fetal serum-containing medium. The cultures used were between 4 and 5 months old and were monitored for continued robust health.
- the Integra bioreactor was provided with normal Eagles minimal essential medium (EMEM) supplemented with exosome-free fetal bovine serum FBS. Additionally fresh media was added to the upper chamber. Supernatant samples were taken at 2, 4, 6, and 24 hours after addition of fresh medium, mixed with protease inhibitor and Venceremin peptide reagent (New England Peptide, Gardner, Mass.) for incubation at 4° C.
- EMEM normal Eagles minimal essential medium
- FBS exosome-free fetal bovine serum
- Venceremin peptides were originally identified as ligands with strong avidity for heat shock proteins, particularly HSP90 and of variable affinity to isoforms of HSP70, HSP60 and other chaperone proteins.
- HSP90 heat shock proteins
- HSP60 variable affinity to isoforms of HSP70, HSP60 and other chaperone proteins.
- the Venceremin peptide Vn96reverse referred to as Heladonin (Hdn: H2N-LKLFEGLTLAGWSFRSLSLGRGKGQSP-OH), was used.
- Integra bioreactor lower chamber supernatant samples (2 mls) were mixed with 101 of protease inhibitor and 50 ⁇ g of Hdn peptide stock solution.
- Microvesicles were prepared from Bioreactor supernatant samples taken at 2, 4, 6 and 24 hours after addition of fresh medium and placed at 4° C.
- Exosome-free fetal bovine serum (FBS) supplement was purchased from Exo-FBS Systems Biosciences, Mountain View Calif. Eagles minimal essential medium (EMEM) supplied by ATCC Cat #30-2003. Complete 10% fetal bovine serum 90% EMEM was placed in the upper reservoir chamber of the CELLine Bioreactor. Prior to introduction of U87 cells into the bioreactor, the bioreactor was provided with Eagle's minimum essential medium+100 U/ml penicillin+100 ⁇ g/ml streptomycin (EMEM)+10% exosome-free fetal bovine serum FBS. After U87 cell introduction into the bioreactor, the bioreactor was cultured at 37° C. in a 5% carbon dioxide atmosphere.
- EMEM Eagle's minimum essential medium
- Upper chamber contains EMEM supplemented regular fetal bovine serum.
- a control bioreactor containing 15 mls of EMEM+Exo-free Medium placed at 37° C. was used. 2mls were taken from the controls each day and replaced with fresh medium.
- TMZ The MW of TMZ is 194.151 g/mol. 100 mg TMZ was dissolved in 5 ml of DMSO (20 mg/ml TMZ), which is equivalent to 20 ⁇ g/ ⁇ l TMZ (257 mM). The stock solution of TMZ was used to provide TMZ at designated concentrations in the culture media of the bioreactor.
- the culture received fresh SBI Exosome-free serum supplemented media in lower chamber and regular FBS-supplemented media in the upper chamber and placed in a 37° C. incubator.
- the bioreactor was retrieved from the incubator and rocked gently for 1 min.
- 2 mls of media were removed from the lower cell chamber and transferred to 2.0 ml HANDEE microcentrifuge tube (PIERCE Rockland II) containing 5 ul of protease inhibitor (Cocktail III, EMD Merck Millipore). 2 mls of fresh media was added to upper chamber to compensate for removal.
- the retrieved volumes of supernatant (SN) were centrifuged at 17000 g for 5 m at 4° C. to pellet microparticulates and cell debris.
- the premixed 4 ⁇ XT loading buffer (Bio-Rad) was adjusted to 4M urea, 25 mM TCEP (reducing agent; PIERCE) and 5 ⁇ l/ml of protease inhibitor (Cocktail III EMD Milipore).
- the electrophoresis sample/loading buffer was referred to as “USB” for urea sample buffer. Samples were incubated at 95° C. in a dry-heating block for 5 minutes, vortexed vigorously and given a 30 s spin in a microcentrifuge to bring down droplets and condensation.
- the blotting module contained pre-chilled Towbin transfer buffer and an ice pack. Blotting was considered complete by running at 90V for 30 m. The blot was rinsed in distilled deionised water and processed with the Pierce reversible protein stain kit. The images were captured using a Bio-Rad Chemi-Doc using white light mode and allowed to dry.
- the blots were destained to clear background by rehydration in ddH2O and use of destaining reagent (PIERCE). The blots were blocked for 30 minutes in 5% low-fat skim milk powder dissolved in phosphate buffered saline adjusted to 0.075% Tween 20 (TPBS).
- the blots were cut longitudinally at the 37 kDa marker (i.e. perpendicular to the direction of electrophoresis) to allow for the same samples to be probed for low molecular weight (bottom) and high molecular weight proteins (top).
- the target was gamma ⁇ H2AX ( ⁇ 17 kDa Anti-phospho-Histone H2A.X_Ser139: Millipore MABE205).
- H2AX i.e. unphosphorylated H2AX anti-Histone H2A.X: Millipore 07-627.
- the antibody-probed and TPBS washed blot halves were covered with 1 ml of Super Signal West Dura HRP substrate (PIERCE), covered with cling film and imaged using the Chemi-Doc at exposures between 2 s and 60 s depending on the signal intensity.
- PIERCE Super Signal West Dura HRP substrate
- U87 cell cultures were grown as a monolayer in T-75 flasks (Corning, 75 cm 2 , ultra low attachment surface). Flask 1 was designated as a control flask, while Flasks 2 and 3 were treated with 50 ⁇ M and 100 ⁇ M TMZ, respectively. U87 s were grown in Eagle's Minimum Essential Medium, fetal bovine serum to a final concentration of 10%. Cells were grown to 80% prior to dosage with TMZ.
- Control and TMZ-treated U87 cells were processed into subcellular fractions using the sub-cellular proteome extraction kit (S-PEK, EMD Milipore) according to manufacturer instructions using differential detergent extraction with four extraction buffers to isolate proteins enriched in various cellular compartments.
- Various buffers were used in the extraction process to enrich for proteins in specified compartments as follows: from the cytoplasmic compartment in Extraction buffer 1 (EB1); enriched in membrane-associated proteins, Extraction buffer 2 (EB2); enriched in nucleus-associated proteins, Extraction buffer 3 (EB3) or enriched in cytoskeletal proteins, Extraction buffer 4 (EB4). All blots on cellular compartment-extracted proteins were conducted as described for microvesicle-isolated proteins.
- H2AX and ⁇ H2AX are Markers of Genotoxic Stress
- Table 2 illustrates the microvesicle samples analyzed in the blot analyses and the corresponding lanes for the respective samples, the results of which are depicted in FIG. 1 and FIG. 2 A, 2 B .
- ⁇ H2AX ( FIG. 2 A ) a band migrating between the 15 and 20 kDa marker was clearly observed at 2, 6 and 24 h after medium replacement, with only a thin band seen at 4 h ( FIG. 2 A , lanes 2, 4, 5 and 3).
- ⁇ H2AX was uniformly intense in 2, 4, 6 and 24 h microvesicles on day 3 following addition of 300 uM temozolomide (TMZ) to the culture media. This study therefore presents the first recorded observation of ⁇ H2AX, a nuclear biomarker reflecting alkylation of DNA, captured in shed microvesicle material.
- ⁇ H2AX on the first day, in the absence of the DNA damaging agent (TMZ), supports the observation that the U87 phenotype is associated with genomic instability due to the observed release of ⁇ H2AX in microvesicles.
- TMZ DNA damaging agent
- ⁇ H2AX became consistent in intensity and was more abundant following addition of TMZ to the culture media. This latter observation indicates that prolonged exposure to TMZ increases the probability that ⁇ H2AX will be incorporated into microvesicles.
- ⁇ H2AX in microvesicles may thus be used as an indicator of phenotypic genomic instability and increased DNA damage due to drug or radiation exposure.
- H2AX ( FIG. 2 B ) the antibody to unphosphorylated H2AX was used secondarily to the same blot probed for ⁇ H2AX. It was observed that the protein expression of H2AX, even in the presence of TMZ, was similar to that observed for ⁇ H2AX. H2AX in microvesicles may thus be used as an indicator of phenotypic genomic instability and increased DNA damage due to drug or radiation exposure.
- H2AX and ⁇ H2AX are Nuclear Proteins
- Table 3 illustrates the subcellular compartment samples analyzed in the blot analyses and the corresponding lanes for the respective samples, the results of which are depicted in FIG. 3 .
- ⁇ H2AX protein could only be detected in nuclear fractions of U87 protein extracts from whole cells, as represented by the single detected band marked with an arrow.
- ⁇ H2AX protein also began to accumulate only in the nucleus following application of TMZ to the cell culture.
- H2AX protein could only be detected in nuclear fractions of U87 protein extracts from whole cells (large arrow).
- a smaller protein was also detected in nuclear extracts (small arrow) with an H2AX antibody, possibly representing a degradation product or fragment of H2AX.
- both ⁇ H2AX and H2AX proteins could only be detected in nuclear fractions of U87 cells, as these proteins were absent from protein extracts enriched for cytoplasmic, membrane-associated, and cytoskeletal proteins.
- microvesicle-derived unphosphorylated H2AX and microvesicle-derived ⁇ H2AX which are both histone proteins, are relevant tumor markers. These protein markers were found to be associated with microvesicles shed from various tumor or tumor-like cell lines, including a cervical cancer model cell line (HELA), a glioma model cell line (U87), and a model highly proliferative renal cell line (HEK293T).
- HELA cervical cancer model cell line
- U87 glioma model cell line
- HEK293T model highly proliferative renal cell line
- HELA ATCC® ccl-2TM
- U87 ATCC® HTB14TM
- HEK293T ATCC® CRL-1573TM
- Integra CELLine Bioreactors Hudson, N.H.
- Upper chambers of the bioreactors were replenished with normal fetal serum-containing medium. The cultures used were between 4 and 5 months old and were monitored for continued robust health.
- Microvesicles in the conditioned media were recovered from culture supernatants using Venceremin peptides (Vn96, New England Peptide, Gardner Mass.) in conjunction with a variety of wash buffers for the disaggregation of microvesicles prior to use of Vn96.
- Microvesicles from these cells were harvested in the conditioned media from the Integra bioreactor lower chamber and supernatant samples (2 mls) were mixed with 1 Oi of protease inhibitor and 50 ⁇ g of Vn96 peptide stock solution.
- Microvesicles were prepared from Bioreactor supernatant samples taken at 2, 4, 6 and 24 hours after addition of fresh medium and placed at 4° C.
- Exosome-free fetal bovine serum (FBS) supplement was purchased from Exo-FBS Systems Biosciences, Mountain View Calif. Eagles minimal essential medium (EMEM) supplied by ATCC Cat #30-2003. Complete 10% fetal bovine serum 90% EMEM was placed in the upper reservoir chamber of the CELLine Bioreactor. Prior to introduction of cells into the bioreactor, the bioreactor was provided with Eagle's minimum essential medium+100 U/ml penicillin+100 ⁇ g/ml streptomycin (EMEM)+10% exosome-free fetal bovine serum FBS. After cells were introduced into the bioreactor, the bioreactor was cultured at 37° C. in a 5% carbon dioxide atmosphere. Upper chamber contains EMEM supplemented regular fetal bovine serum.
- Raw Stock Solutions containing U87, HELA, or HEK293T (293T) bioreactor culture medium were concentrated by VivaSpin 1 million Dalton molecular weight cut off (MWCO) spin filters and resuspended in 50 mM amino acid solution (Stock B) or 5% detergent (Stock D). These solutions were prepared for electrophoresis directly by adding 50 ⁇ l of 3 ⁇ urea SDS sample buffer (USB) to 100 ⁇ l of the stock solutions. After heating at 95° C., 15 ⁇ l were loaded. Samples of Stock B and Stock D can be seen in lanes 2 and 3 of each blot ( FIG. 4 ).
- MWCO molecular weight cut off
- Peptide recovered microvesicles using Vn96 were prepared by incubating 1.8 ml volumes of CELLiNE Integra bioreactor culture media from U87, HELA, or 293T cells with 50 ⁇ g of peptide overnight at 4° C. After incubation of the mixtures were centrifuged at 4500 g washed by resuspending in 500 ⁇ l of Stock B and re-pelleted by centrifugation. The supernatant was removed and the pellet resuspended in 200 ⁇ l of 1 ⁇ urea SDS sample buffer (USB). 15 ⁇ l were loaded to the gel. U87, HELA and 293T microvesicle samples are shown in lanes 4-6 of FIG. 4 . Other samples in FIG. 4 were collected by PD-10 size exclusion chromatography (SEC) using 2% agarose beads and selected buffers.
- SEC size exclusion chromatography
- fractions 2, 3, 4, and 5 1 ml sample volumes and 1 ml eluate fractions were collected by gel filtration procedure PD-10 SEC as discussed herein to form the contents of peak 1 (fractions 2, 3, 4, and 5).
- fractions 2 and 3 were reduced to minimal volume in a VivaSpin 2 ml 1 million Dalton molecular weight cut off (MWCO) spin filter; fractions 4 and 5 were added on top of the retentate of 2 and 3 and again centrifuged to minimum volume. Samples consisting of fractions 2, 3, 4, and 5, otherwise known as peak 1, were pooled and resuspended in 1 ml of water.
- MWCO molecular weight cut off
- the remaining 500 ⁇ l was centrifuged to minimum volume and resuspended in 150 ⁇ l of 1 ⁇ urea SDS sample buffer (USB). 15 ⁇ l were loaded to the gel.
- the concentrated pooled peak 1 fractions were prepared from U87 bioreactor culture medium that had been concentrated by VivaSpin 1 million Dalton molecular weight cut off (MWCO) spin filters and resuspended in AB Serum (Stock A) as indicated above following the PD-10 fractionation into 1 ml volumes fractions 2, 3, and 4.
- Fractions were analyzed via bottom-up LC-MS/MS on a Thermo LTQ mass spectrometer and identified using Scaffold (Proteome Software) and Bioworks, and quantified via spectral counting according to Yates et al. (2004).
- the blotting module contained pre-chilled Towbin transfer buffer and an ice pack. Blotting was considered complete by running at 90V for 30 m. The blot was rinsed in distilled deionised water and processed with the Pierce reversible protein stain kit. The images were captured using a Bio-Rad Chemi-Doc using white light mode and allowed to dry.
- the blots were destained to clear background by rehydration in ddH2O and use of destaining reagent (PIERCE). The blots were blocked for 30 minutes in 5% low-fat skim milk powder dissolved in phosphate buffered saline adjusted to 0.075% Tween 20 (TPBS).
- the blots were cut longitudinally at the 37 kDa marker (i.e. perpendicular to the direction of electrophoresis) to allow for the same samples to be probed for low molecular weight (bottom) and high molecular weight proteins (top).
- the target was gamma ⁇ H2AX ( ⁇ 17 kDa Anti-phospho-Histone H2A.X_Ser139: Millipore MABE205).
- H2AX i.e. unphosphorylated H2AX anti-Histone H2A.X: Millipore 07-627.
- the blots were probed for the presence of pan Histones using the Anti-Histone H4 Antibody: Millipore 04-858.
- the antibody-probed and TPBS washed blot halves were covered with 1 ml of Super Signal West Dura HRP substrate (PIERCE), covered with cling film and imaged using the Chemi-Doc at exposures between 2 s and 60 s depending on the signal intensity.
- PIERCE Super Signal West Dura HRP substrate
- Table 4 illustrates the microvesicle samples analyzed in the blot analyses and the corresponding lanes for the respective samples, the results of which are depicted in FIG. 4 .
- the blots described above were probed to detect specific proteins in the various samples (See Table 4 and FIG. 4 ). In all instances with the exception of CD63, the detection of all proteins was strongest in the peptide recovered microvesicle fractions (microvesicle samples). Antibodies to all histones (pan-histone), H2AX, and ⁇ H2AX were strongly represented in the microvesicle samples (lanes 4, 5, and 6), but could not be detected in the stock solution lanes (lanes 2 and 3), which were obtained from cell culture samples and not enriched for microvesicles. Histones are a surface feature of rapidly dividing cells, such as cancers. The data presented in FIG. 4 suggests that histones are incorporated into shed microvesicles from tumor cells.
- histones may be part of nucleosomes, they may be shed from the cells in membranous form.
- the rich presence of histones in the tumor cell-derived microvesicle samples could also be detected by analysis with mass spectrometry, as shown in Table 5 below.
- histone proteins such as H2AX and ⁇ H2AX, are enriched in tumor-derived microvesicles. This suggests that histone proteins may be useful as tumor markers.
Abstract
The invention described herein relates to methods of monitoring genotoxic stress in a test subject, specifically by detecting the expression level of microvesicle-associated H2AX from a biological sample.
Description
- This application claims the benefit of U.S. Provisional Application No. 61/785,552 filed Mar. 14, 2013, which is incorporated herein by reference in its entirety.
- The present disclosure relates to methods of monitoring genotoxic stress in a test subject, specifically by detecting the expression level of microvesicle-associated H2AX from a biological sample.
- Agents that damage DNA or interfere with replication can be present in the environment, accidentally released, and/or intentionally administered. Exposure to these agents causes genotoxic stress in a wide variety of organisms. To assess the extent of damage/interference and whether such effects outweigh potential benefits arising from use of the agent, it is necessary to monitor, detect and/or measure genotoxic stress.
- Agents that damage DNA or interfere with replication are commonly administered as a part of cancer treatment. Cancer is a leading cause of death worldwide. In 2004, it accounted for 7.4 million deaths (around 13% of all deaths). Deaths from cancer are expected to continue to rise, with a predicted 12 million deaths in 2030 (WHO, February 2009). Various treatments are available for cancer patients, such as chemotherapy, radiation, surgery, and drug therapy. Effective monitoring of cancer progression and treatment efficacy are critical to reducing the worldwide cancer burden, yet the development of robust and non-invasive methods and tools for monitoring disease progression and treatment efficacy remain major challenges in the field. Furthermore, a large proportion of patients with cancer, such as breast cancer and prostate cancer, are over-treated, resulting in wasted time and expense and unnecessary exposure of patients to unpleasant treatments and dangerous side effects (Hartmann et al., Lancet 2010, 11: 383-390). Effective, non-invasive monitoring of a patient's response to a treatment would greatly improve the efficiency of cancer management.
- For many types of cancers, the current means of monitoring the efficacy of a given treatment of cancer in the patient involve histopathology of a tissue sample or imaging studies, which involve painful and invasive biopsies or risks associated with imaging such as exposure to radiation. These processes are often uncomfortable, expensive and inaccurate due to subjective interpretation by different technicians and clinicians. Thus, a need remains for sensitive, non-invasive, and rapid means for monitoring the efficacy of a given treatment for cancer patients.
- Expression levels of specific proteins have been shown to have potential as an informative and reliable tool for making diagnoses, monitoring the efficacy of cancer treatment, and predicting prognoses. However, very few protein diagnostic markers have been developed to date (Anderson and Anderson, Mol Cell Proteomics 2002, 1.11: 845-867; Sanchez-Carbayo, Tumor Biol 2010, 31: 103-112).
- An unmet need exists in the field of cancer biology for better methods of monitoring the efficacy of treatment in cancer patients. Ideally these methods would be less invasive and less painful and discomforting than are currently available monitoring techniques.
- The invention described herein meets the needs described above by providing methods of monitoring genotoxic stress in a test subject, specifically by detecting the expression level of microvesicle-associated H2AX in a biological sample. The H2AX to be detected may either be unphosphorylated or phosphorylated. In certain embodiments the phosphorylated H2AX is γH2AX.
- In some embodiments, the genotoxic stress is due to environmental contamination or radiation exposure. In other embodiments, the genotoxic stress is due to cancer treatment, such as administration of an anti-cancer agent or exposure to radiation. Thus, methods described herein include methods of monitoring genotoxic stress due to cancer treatment in a test subject by detecting the expression level of microvesicle-associated H2AX in a test subject, and monitoring the cancer treatment in the subject based on the expression level of the microvesicle-associated H2AX. In some embodiments, detecting the expression level of microvesicle-associated H2AX in a biological sample from the test subject occurs at a plurality of time points following administration of the cancer treatment.
- In certain embodiments of the above aspect, the cancer treatment includes administration of an anti-cancer agent such as a platinum analogue, a tetrazine, an anti-metabolite, a plant alkaloid or terpenoid, a cytotoxic antibiotic, a DNA alkylating agent (e.g., temozolomide), or a type I topoisomerase inhibitor (e.g., indenoisoquinoline).
- In certain embodiments, monitoring the genotoxic stress involves comparing the expression level of H2AX in the biological sample from the test subject with the expression level of H2AX in a biological sample from a control subject that is not given the cancer treatment.
- In certain embodiments, a higher level of expression of H2AX in the biological sample from the test subject compared to the level of expression of H2AX in the biological sample from the control subject may indicate that the cancer treatment is inhibiting replication of DNA in cancer cells in the test subject.
- In some embodiments, monitoring the genotoxic stress involves evaluating the efficacy of the cancer treatment. In preferred embodiments, evaluating the efficacy of the cancer treatment in the test subject involves comparing the expression level of H2AX in the biological sample from the test subject with the expression level of H2AX in biological samples from a plurality of control subjects.
- In certain embodiments, the plurality of control subjects have the same type of cancer as the test subject and are administered the same cancer treatment as the test subject. In other preferred embodiments, the cancer treatment has a different level of treatment efficacy in each of the plurality of control subjects.
- In some embodiments, a step is included for deriving a score from the comparison of the expression level of H2AX in the biological sample from the test subject with the expression level of H2AX in the biological samples from the plurality of control subjects, where the score indicates a level of similarity between the expression level of H2AX in the biological sample from the test subject and the expression level of H2AX in the biological samples from the plurality of control subjects. In preferred embodiments, determining the level of efficacy of the cancer treatment in the test subject is based on the above mentioned score. In additional preferred embodiments, the score used in determining the efficacy of the cancer treatment in the test subject is a correlation coefficient.
- In preferred embodiments, the cancer in the above embodiments is a solid tumor. In other embodiments, the cancer is pancreatic, ovarian, adenocarcinoma, prostate, breast, brain, head, neck, cervical, or lymphoma cancers. The brain cancer can be glioblastoma multiforme (WHO grade III and IV) or lower grade malignancies including, for example, anaplastic astrocytoma, oligoastrocytoma, oligodendrogliomas; ependymoma, medulloblastoma, meningioma, pineal tumors, or pituitary tumors.
- In certain embodiments, the biological sample in the above embodiments is plasma, serum, cerebrospinal fluid, urine, tears, milk, lymph fluid, synovial fluid, bronchoalveolar lavage, amniotic fluid, saliva, ocular fluid, ascites, and respiratory droplets.
- In certain embodiments, detecting the expression level of H2AX involves detecting binding of H2AX to an H2AX-specific antibody. In preferred embodiments, the antibody is covalently bound to a bead. In yet additional preferred embodiments, detecting binding of H2AX to an H2AX-specific antibody involves detecting fluorescence. In other embodiments, detecting the expression level of microvesicle-associated H2AX involves the use of ELISA, flow cytometry, or liquid chromatography-mass spectrometry.
- In certain embodiments, isolating microvesicles from the biological sample prior to detecting the expression level of H2AX involves contacting the biological sample with a cancer-derived microvesicle-specific reagent where the biological sample includes microvesicles and the reagent binds to the microvesicles, contacting the microvesicles with a tissue-specific reagent, and isolating the microvesicles derived from the tissue.
- Certain aspects of the present disclosure relate to methods of monitoring genotoxic stress in a test subject by detecting the expression level of microvesicle-associated histone proteins in a biological sample from the test subject, and monitoring genotoxic stress in the subject based on the expression level of the microvesicle-associated histone protein.
-
FIG. 1 illustrates a Western gel blot analysis of U87 brain tumor cell-shed microvesicle-derived total protein content from various microvesicle samples as a function of time or exposure to chemotherapeutic agent temozolomide (TMZ). -
FIG. 2A illustrates a Western blot analysis of γH2AX protein present in the various microvesicle samples.FIG. 2B illustrates a Western blot analysis of H2AX protein present in the various microvesicle samples. -
FIG. 3A illustrates a Western blot analysis of γH2AX protein present in various subcellular compartment samples from cells of the U87 tumor colony.FIG. 3B illustrates a Western blot analysis of H2AX protein present in various subcellular compartment samples. -
FIG. 3C illustrates a legend of the subcellular compartments analyzed in the blot and their respective labels. -
FIG. 4 illustrates a Western blot analysis of H2AX, γH2AX, and pan-Histone proteins present in microvesicle preparations from U87, Hela, and HEK293T cells under various conditions. - The present disclosure relates to methods of monitoring genotoxic stress in a test subject, specifically by detecting the expression level of microvesicle-associated H2AX, either unphosphorylated or in its phosphorylated form (e.g., γH2AX), in a biological sample.
- Histones are proteins which package DNA into nucleosomes, the repeating units that make up chromatin. Histone H2A is one of the five types of histone proteins. There are several non-allelic variants of histone H2A. The variant histone H2AX has a C terminal tail that is used for DNA repair.
- Without wishing to be bound by theory, it is believed that H2AX and γH2AX are markers for genotoxic stress due to the role that histones play in packaging DNA into nucleosomes. Furthermore, phosphorylation of histone H2AX to γH2AX (ser 139) is a robust early indicator of DNA damage such as double stranded breaks (DSBs).
- Thus, the present disclosure includes the discovery of a non-invasive method for monitoring genotoxic stress in a test subject by detecting the expression level of H2AX associated with microvesicles.
- Genotoxic stress in a test subject can be induced by a variety of circumstances, for example, accidental exposure of subjects to genotoxins (e.g., environmental contamination) or radiation, hostile exposure to genotoxins or radiation, and cancer treatment designed to slow or stop the growth of rapidly dividing cancer cells. It should be understood by one of skill in the art that the embodiments described herein with respect to methods for monitoring genotoxic stress due to cancer treatment are also embodiments of methods for monitoring genotoxic stress induced by other circumstances.
- In order to facilitate an understanding of the disclosure, selected terms used in the application will be discussed below.
- “γH2AX” as used herein refers to a gamma-phosphorylated H2AX protein (i.e., phosphorylated on Serine 137). H2AX is a variant of the histone protein H2A.
- When the term “H2AX” is used herein, it refers to all derivatives of H2AX, including both the unphosphorylated and phosphorylated forms of the protein. The phosphorylated residue of the derivative may be Serine 137 or another residue.
- “Monitoring” as used herein refers to the act of observing. Monitoring a treatment may include observing a change in the expression level of a protein in an individual receiving that treatment over time.
- “Microvesicle” as used herein refers to any small vesicle released from any cell type. Microvesicles include, for example, endosome-derived exosomes, plasma membrane-derived shedding vesicles, apoptotic bodies, prostasomes, P2 and P4 particles, and outer membrane vesicles (OMVs). Shedding vesicles may be referred to as ectosomes, microparticles, shedding bodies, exovesicles, or secretory vesicles. Protasomes may be referred to as aposomes or seminosomes. P2 and P4 particles may be referred to as prominosomes.
- A “microvesicle-associated protein” as used herein refers to any protein that has been contained within or located on the surface of a microvesicle. “Microvesicle-associated protein” can refer to such a protein while the protein is still associated with a microvesicle or after the protein is no longer associated with a microvesicle. In preferred embodiments, the microvesicle-associated protein is γH2AX.
- Described herein are methods of monitoring, detecting or measuring genotoxic stress due to cancer treatment, specifically by detecting the expression level of microvesicle-associated H2AX in a biological sample from a test subject.
- The cancer treatment may be any treatment which is used to slow or stop the progression of the cancer. Such treatments may work via a wide variety of mechanisms ranging from alkylating DNA to interfering with other aspects of the DNA replication process. Exemplary methods include treatment with anti-cancer agents and/or exposure to radiation.
- Anti-cancer agents include classical DNA alkylating agents such as temozolomide; nitrogen mustard; cyclophosphamide; mechlorethamine or mustine (HN2) (trade name Mustardgen); uramustine or uracil mustard; melphalan; chlorambucil; ifosfamide; nitrosoureas such as carmustine, lomustine and streptozocin; alkyl sulfonates such as busulfan; and Thiotepa. Certain alkylating agents are described as “non-classical”. Examples of non-classical alkylating agents include procarbazine and altretamine.
- Other anti-cancer agents are considered to be alkylating-like, since they do not have an alkylating group, but nevertheless damage DNA. Alkylating-like drugs include the platinum-based chemotherapeutic drugs (termed platinum analogues) such as cisplatin, carboplatin, nedaplatin, oxaliplatin, satraplatin, and triplatin tetranitrate,
- In some embodiments, the anti-cancer agent is a tetrazine, e.g., dacarbazine, mitozolomide, or temozolomide.
- Other exemplary anti-cancer agents include anti-metabolites which mimic purines (e.g., azathioprine, mercaptopurine) or pyrimidines and become incorporated into the DNA.
- Additional exemplary anti-cancer agents are the plant alkaloids and terpenoids, which block cell division by preventing microtubule function. The main examples of such anti-cancer agents are Vinca alkaloids and taxanes. The Vinca alkaloids include, without limitation, vincristine, vinblastine, vinorelbine, and vindesine. The taxanes include, without limitation, paclitaxel, originally known as Taxol and docetaxel. a semi-synthetic analogue of paclitaxel.
- Anti-cancer agents also include topoisomerase inhibitors. Type I topoisomerase inhibitors include the camptothecins, irinotecan and topotecan. Type II inhibitors include amsacrine, etoposide, etoposide phosphate, and teniposide. These are semisynthetic derivatives of epipodophyllotoxins.
- Anti-cancer agents also include cytotoxic antibiotics, for example, actinomycin, anthracyclines (e.g., doxorubicin, daunorubicin, vahrubicin, idarubicin, epirubicin), bleomycin, plicamycin, and mitomycin.
- In certain embodiments, the anti-cancer agents are DNA alkylating agents, such as temozolomide, or topoisomerase inhibitors, such as indenoisoquinoline,
- The indenoisoquinoline may include, without limitation, National Cancer Institute lead compounds NSC 706744, NSC 725776 (Indimitecan), NSC 724998 (Indotecan), as well as 6-Ethyl-5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline, 5,6-Dihydro-5,11-diketo-6-propyl-11H-indeno[1,2-c]isoquinoline, 6-Cyclopropyl-5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline, 5,6-Dihydro-5,11-diketo-6(methoxycarbonylmethyl)-11H-indeno[1,2-c]isoquinoline, 5,6-Dihydro-6-(4-hydroxy-1-butyl)-5,11-diketollH-indeno[1,2-c]isoquinoline, 5,6-Dihydroxy-6-(5-hydroxy-1-pentyl)-5,11-diketollH-indeno[1,2-c]isoquinoline, cis-4-Carboxy-3,4-dihydro-N-methyl-3-(3′,4′methylenedioxyphenyl)-1(2H)isoquinolone, 5,6-Dihydro-5,11-diketo-6-methyl-8,9methylenedioxy-11H-indeno[1,2-c]isoquinoline, cis-N-(1-Butyl)-4-carboxy-3,4-dihydro-3-(3′,4′methylenedioxyphenyl)-1(2H)-isoquinolone, 6-(1-Butyl)-5,6-dihydro-5,11-diketo-8,9methylenedioxy-11H-indeno[1,2-c]isoquinoline, cis-N-Ally-4-carboxy-3,4-dihydro-6,7-dimethoxy-3(3′,4′-methylenedioxy phenyl)-1(2H)isoquinolone, 6-Allyl-2,3-dimethoxy-5,6-dihydro-5,11-oxo-8,9(methylenedioxy)-11H-indeno[1,2c]isoquinoline, cis-N-(1-Butyl)-4-carboxy-3,4-dihydro-6,7dimethoxy-3-(3′,4′methylenedioxyphenyl)-1(2H)isoquinolone, 6-(1-Butyl)-5,6-dihydro-5,11-diketo-2,3-dimethoxy8,9-methylenedioxy11H-indeno[1,2-c]isoquinoline, cis-N-Benzyl-4-carboxy-3,4-dihydro-6,7-dimethoxy3-(3′,4′-methylenedioxyphenyl)-1(2H)isoquinolone, 6-Benzyl-5,6-dihydro-5,11-diketo 2,3-dimethoxy-8,9-methylenedioxy-11H-indeno[1,2-c]isoquinoline, cis-N-(p-Anisyl)-4-carboxy-3,4-dihydro-6,7dimethoxy-3-(3′,4′-methylene-dioxyphenyl)-1(2H)isoquinolone, 6-(p-Anisyl)-2,3-dimethoxy-5,6-dihydro-5,11diketo-8,9-methylenedioxy-11H-indeno[1,2-c]isoquinoline, cis-3-(3′,4′-Dibenzyloxyphenyl)-4-carboxy-3,4dihydro-N-methyl-1-2H-isoquinolone, 8,9-Dibenzyloxy-5,6-dihydro-5,11-diketo-6-methyl11H-indeno[1,2-c]isoquinoline, cis-3-(3′,4′-Dibenzyloxyphenyl)-4-carboxy-3,4dihydro-N-methyl-6,7-dimethoxy-1-(2H)-isoquinolone, 8,9-Dibenzyloxy-5,6-dihydro-5,11-diketo-6-methyl2,3-dimethoxy-11H-indeno[1,2-c]isoquinoline, cis-4-Carboxy-3,4-dihydro-N-methyl-6,7dimethoxy-3-(3′,4′,5′-trimethoxyphenyl)-1(2H)isoquinolone, 5,6-Dihydro-5,11-diketo-6methyl-2,3,8,9,10pentamethoxy-11H-indeno[1,c]isoquinoline, cis-4-Carboxy-3,4-dihydro-N-methyl-3(3′,4′,5′trimethoxyphenyl)-1(2H)isoquinolone, 5,6-Dihydro-5,11-diketo-6-methyl-8,9,1Otrimethoxy-11H-indeno[1,2-c]isoquinoline, cis-4-Carboxy-N-ethyl-3-(3′,4′-methylenedioxyphenyl)-6,7-dimethoxy3,4-dihydro-1(2H)isoquinolone, 6-Ethyl-5,6-dihydro-5,11-diketo-2,3-dimethoxy-8,9methylenedioxy-11H-indeno[1,2-c]isoquinoline, 5,6-Dihydro-5,11-diketo-6-(4-hydroxybut-1-yl)-2,3dimethoxy-8,9-methylenedioxy-(11H)indeno[1,2-c]isoquinoline, 5,6-Dihydro-6-(4-hydroxypent-1-yl)-5,11-diketo-2,3-dimethoxy-8,9-methylenedioxy-11Hindenoisoquinoline, cis-5,6,12,13-Tetrahydro-2,3-dimethoxy-6-methyl-5,11-dioxo-8,9(methylenedioxy)-(11H)indeno[1,2-c]isoquinoline, cis-6-Ethyl-5,6,12,13-tetrahydro-2,3-dimethoxy-5,11-dioxo-8,9-(methylene-dioxy)-11H-indeno[1,2-c]isoquinoline, cis-6-Allyl-5,6,12,13-tetrahydro-2,3-dimethoxy-5,11-dioxo-8,9-(methylenedioxy)-(11H)indeno[1,2-c]isoquinoline, 5,6-Dihydro-5,11-diketo-2,3,8-trimethoxy-6-methyl9[(methylsulfonyl)oxy]-(11H)indeno[1,2-c]isoquinoline, 6-Ethyl-5,6,12a,13a-tetrahydro-11-hydroxy-2,3dimethoxy-8,9-(methylenedioxy)-5-oxo-11H-indeno[1,2-c]isoquinoline, 6-Ethyl-5,6,12a,13a-tetrahydro-11˜-hydroxy-2,3dimethoxy-8,9-(methylenedioxy)-11H-indeno[1,2-c]isoquinoline, 6-(3-Carboxy-1-propyl)-5,6-dihydro-5,11-diketol1H-indeno[1,2-c]isoquinoline, or 6-Ethyl-2,3-dimethoxy-8,9-(methylenedioxy)-11Hindeno[1,2-c]isoquinolinium Chloride.
- In certain embodiments, detecting the expression level of microvesicle-associated γH2AX in a biological sample from the test subject occurs at a plurality of time points following administration of the cancer treatment.
- In certain embodiments, as disclosed herein, detecting the expression level of microvesicle-associated H2AX in a biological sample from the test subject following cancer treatment occurs at least after one day, at least after 3 days, at least after 4 days, at least after 5 days, at least after 6 days, at least after 7 days, at least after 8 days, at least after 10 days, at least after 12 days, at least after 14 days, at least after 16 days, at least after 18 days, at least after 20 days, at least after 21 days, at least after 25 days, at least after 30 days, at least after 2 months, at least after 4 months, at least after 6 months, at least after 8 months, at least or after 12 months.
- In preferred embodiments, monitoring the cancer treatment involves comparing the expression level of H2AX in the biological sample from the test subject with the expression level of H2AX in a biological sample from a control subject that is not given the cancer treatment.
- In certain embodiments, a higher level of expression of H2AX in the biological sample from the test subject compared to the level of expression of H2AX in the biological sample from the control subject indicates that the cancer treatment is inducing genotoxic stress in the test subject. Typically, an expression level is said to be increased or decreased relative to a second expression level if the difference between the two expression levels is statistically significant. The difference between two levels is considered to be statistically significant if it was unlikely to have occurred by chance. Statistical significance may be measured by any means known in the art, such as, for example, Fisherian statistical hypothesis testing or the Neyman-Pearson lemma.
- In certain embodiments, monitoring the cancer treatment includes evaluating the efficacy of the cancer treatment in the test subject. Evaluating the efficacy may include methods of comparing the expression level of H2AX in the biological sample from the test subject with the expression level of H2AX in biological samples from a plurality of control subjects. Evaluating the efficacy may further include methods for assigning a score to the test subject based on expression levels of H2AX in test subjects compared to control subjects.
- Typically, each of the plurality of control subjects has the same type of cancer as the test subject and is administered the same cancer treatment as the test subject.
- In certain embodiments, the cancer treatment has a different level of treatment efficacy in each of the plurality of control subjects.
- In certain embodiments, a step is included for deriving a score from the comparison of the expression level of H2AX in the biological sample from the test subject with the expression level of H2AX in the biological samples from the plurality of control subjects, where the score indicates a level of similarity between the expression level of H2AX in the biological sample from the test subject and the expression level of H2AX in the biological samples from the plurality of control subjects. In preferred embodiments, determining the level of efficacy of the cancer treatment in the test subject is based on the above mentioned score.
- The score may be derived by any methods known to one of skill in the art. In certain embodiments, the score may simply be a measure of the difference in expression levels. In preferred embodiments, the score is a correlation coefficient. A correlation coefficient describes the similarity between two expression patterns. Expression levels may be considered similar if the correlation coefficient is greater than or equal to 0.5. In preferred embodiments, for expression levels to be considered significantly similar, the correlation coefficient should be greater than 0.6, 0.7, 0.8, 0.9, or 0.95. In other embodiments, the score is generated by other statistical methods which produce a measure of mutual information to describe the similarity between two expression patterns. Expression levels may be considered similar if the normalized mutual information value is greater than or equal to 0.7. In preferred embodiments, for the expression levels to be considered significantly similar, the normalized mutual information value should be greater than 0.8, 0.9, or 0.95.
- If the score indicates a significant level of similarity between the expression level of microvesicle-associated H2AX in the biological sample from the test subject and the expression level of microvesicle-associated H2AX in biological samples from the plurality of control subjects, then the test subject can be said to have or to be likely to have the same efficacy of cancer treatment as that of the plurality of control subjects. For example, if the score indicates a significant level of similarity between the expression level of H2AX in the biological sample from the test subject and the expression level of H2AX in biological samples from the plurality of control subjects who are not given the cancer treatment, then the cancer treatment can be said to be or likely to be efficacious.
- The described methods may be applied to treatment of any type of cancer including, without limitation, adult acute lymphoblastic leukemia, childhood acute lymphoblastic leukemia, adult acute myeloid leukemia, childhood acute myeloid leukemia, adrenocortical carcinoma, childhood adrenocortical carcinoma, aids-related cancers, aids-related lymphoma, anal cancer, appendix cancer, basal cell carcinoma, extrahepatic bile duct cancer, bladder cancer, childhood bladder cancer, bone cancer, osteosarcoma and malignant fibrous histiocytoma, childhood brain stem glioma, adult brain tumor, childhood central nervous system atypical teratoid/rhabdoid tumor, childhood central nervous system embryonal tumors, childhood astrocytomas, childhood pineal parenchymal tumors of intermediate differentiation, childhood supratentorial primitive neuroectodermal tumors and pineoblastoma, childhood brain and spinal cord tumors, breast cancer, childhood breast cancer, male breast cancer, childhood bronchial tumors, burkitt lymphoma, childhood carcinoid tumor, primary central nervous system lymphoma, cervical cancer, childhood cervical cancer, childhood chordoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative disorders, colon cancer, childhood colorectal cancer, childhood craniopharyngioma, childhood central nervous system embryonal tumors, endometrial cancer, childhood ependymoblastoma, childhood ependymoma, esophageal cancer, childhood esophageal cancer, Ewing sarcoma family of tumors, childhood extracranial germ cell tumor, extragonadal germ cell tumor, gallbladder cancer, gastric (stomach) cancer, childhood gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (gist), childhood gastrointestinal stromal cell tumor, extragonadal germ cell tumor, ovarian germ cell tumor, gestational trophoblastic tumor, adult glioma, hairy cell leukemia, head and neck cancer, adult (primary) hepatocellular (liver) cancer, childhood (primary) hepatocellular (liver) cancer, adult Hodgkin lymphoma, childhood Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumors (endocrine pancreas), Kaposi sarcoma, kidney (renal cell) cancer, childhood kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, childhood laryngeal cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, lip and oral cavity cancer, adult (primary) liver cancer, childhood (primary) liver cancer, non-small cell lung cancer, small cell lung cancer, adult non-Hodgkin lymphoma, childhood non-Hodgkin lymphoma, primary central nervous system lymphoma, Waldenström macroglobulinemia, malignant fibrous histiocytoma of bone and osteosarcoma, childhood medulloblastoma, childhood medulloepithelioma, melanoma, Merkel cell carcinoma, adult malignant mesothelioma, childhood mesothelioma, metastatic squamous neck cancer with occult primary, mouth cancer, childhood multiple endocrine neoplasia syndrome, multiple myeloma/plasma cell neoplasm, mycosis fungoides, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, chronic myelogenous leukemia, multiple myeloma, chronic myeloproliferative disorders, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, childhood nasopharyngeal cancer, neuroblastoma, childhood oral cancer, oropharyngeal cancer, childhood ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, childhood pancreatic cancer, childhood papillomatosis, parathyroid cancer, penile cancer, pharyngeal cancer, pituitary tumor, plasma cell neoplasm/multiple myeloma, pleuropulmonary blastoma, prostate cancer, rectal cancer, respiratory tract carcinoma involving the nut gene on chromosome 15, retinoblastoma, childhood rhabdomyosarcoma, salivary gland cancer, childhood salivary gland cancer, adult soft tissue sarcoma, childhood soft tissue sarcoma, uterine sarcoma, Sézary syndrome, skin cancer (nonmelanoma), childhood skin cancer, skin cancer (melanoma), Merkel cell skin carcinoma, small intestine cancer, adult soft tissue sarcoma, childhood soft tissue sarcoma, squamous cell carcinoma, cutaneous t-cell lymphoma, testicular cancer, throat cancer, thymoma and thymic carcinoma, childhood thymoma and thymic carcinoma, thyroid cancer, childhood thyroid cancer, gestational trophoblastic tumor, transitional cell cancer of ureter and renal pelvis, urethral cancer, endometrial uterine cancer, uterine sarcoma, vaginal cancer, childhood vaginal cancer, vulvar cancer, or Wilms' tumor. The brain cancer can be glioblastoma multiforme (WHO grade III and IV) or lower grade malignancies including, for example, anaplastic astrocytoma, oligoastrocytoma, oligodendrogliomas; ependymoma, medulloblastoma, meningioma, pineal tumors, or pituitary tumors.
- In some embodiments, treatment is for cancer that is a solid tumor. In other embodiments, the treatment is for a blood cancer such as leukemia, lymphoma, and myeloma. In certain embodiments, the cancer is selected from pancreatic, ovarian, adenocarcinoma, brain, prostate, breast, head, neck, or lymphoma cancers. In certain embodiments the cancer is a glioma, such as glioblastoma multiforme.
- Methods of the present disclosure include a step of detecting the expression level of microvesicle-associated H2AX, either when associated with the microvesicle or subsequent to dissociation from the microvesicle.
- Protein level of H2AX is detected. In preferred embodiments, detecting the expression level of H2AX involves detecting binding of H2AX to an H2AX-specific antibody, e.g., ELISA. In additional preferred embodiments, the antibody is covalently bound to a bead. In yet additional preferred embodiments, detecting binding of H2AX to an H2AX-specific antibody involves detecting fluorescence. In other embodiments, the level of H2AX is measured directly, using for example, flow cytometry or a liquid chromatography-mass spectrometry.
- In other embodiments, the method involves isolating cancer-derived microvesicles from the biological sample prior to detecting the expression level of H2AX. In preferred embodiments, isolating microvesicles from the biological sample prior to detecting the expression level of H2AX involves contacting the biological sample with a cancer-derived microvesicle-specific reagent where the biological sample includes microvesicles and the reagent binds to the microvesicles, contacting the microvesicles with a tissue-specific reagent, and isolating the microvesicles derived from the tissue.
- The expression level of H2AX may include a relative or absolute amount of a protein in a sample, or it may simply refer to the presence or absence of a protein in a sample. The expression level of the microvesicle-associated H2AX may be detected by any methods known to one of skill in the art (see, for example: Coligan et al,
Unit 9, Current Protocols in Immunology, Wiley Interscience, 1994), which include, without limitation: immunohistochemistry (Microscopy, Immunohistochemistry and Antigen Retrieval Methods for Light and Electron Microscopy, M. A. Hayat (Author), Kluwer Academic Publishers, 2002; Brown C.: “Antigen retrieval methods for immunohistochemistry,” Toxicol Pathol 1998; 26(6): 830-1), ELISA (Onorato et al., “Immunohistochemical and ELISA assays for biomarkers of oxidative stress in aging and disease,” Ann NY Acad Sci 1998 20; 854: 277-90), Western blotting (Laemmeli U K: “Cleavage of structural proteins during the assembly of the head of a bacteriophage T4,” Nature 1970; 227: 680-685; Egger & Bienz, “Protein (western) blotting”, Mol Biotechnol 1994; 1(3): 289-305), and antibody microarray hybridization (Huang, “Detection of multiple proteins in an antibody-based protein microarray system,” Immunol Methods 2001 1; 255 (1-2): 1-13). - Typically, one of two approaches may be used in preparation for detecting the expression levels of the microvesicle-associated H2AX. In the first approach, the protein is dissociated from microvesicles. For example, the microvesicles are lysed, and the proteins in the microvesicles are extracted, precipitated, and reconstituted for analysis. In the second approach, the microvesicles are kept intact so that the protein remains associated, and the microvesicles are attached to a column, resin, or bead. The reconstituted protein or the microvesicles attached to a column, resin, or bead are used in the detection step. For example, the reconstituted protein or the microvesicles attached to a column, resin, or bead are contacted with an antibody specific to the H2AX biomarker.
- In preferred embodiments, detecting the expression level includes detecting binding of H2AX to an antibody specific to this protein. Antibodies may be monoclonal or polyclonal, and they may be obtained from a commercial source or generated for use in the methods described herein. Methods for producing and evaluating antibodies are well known in the art, see, e.g., Coligan, (1997) Current Protocols in Immunology, John Wiley & Sons, Inc; and Harlow and Lane (1989) Antibodies: A Laboratory Manual, Cold Spring Harbor Press, NY (“Harlow and Lane”).
- The antibody may be covalently bound to a bead or fixed on a solid surface, such as glass, plastic, or silicon chip. Typically, the biological sample is contacted with an antibody specific to H2AX. Any H2AX protein present in the sample will bind to the H2AX antibody. The mixture is washed, and the antibody-protein biomarker complexes can be detected. In preferred embodiments, H2AX is detected after the protein binds to an anti-H2AX antibody that is bound to a bead.
- This detection can be achieved by contacting the washed antibody-protein biomarker complexes with a detection reagent. This detection reagent may be, for example, a secondary antibody which is labeled with a detectable label. Exemplary detectable labels include magnetic beads (e.g., DYNABEADS™), fluorescent dyes, radiolabels, enzymes (e.g., horseradish peroxide, alkaline phosphatase, and others commonly used in ELISA), and colorimetric labels such as colloidal gold, colored glass, or plastic beads. In preferred embodiments, H2AX is detected after the protein binds to an anti-H2AX antibody and includes detection of fluorescence.
- Methods for measuring the amount of, or presence of, antibody-marker complexes include, for example, detection of fluorescence, luminescence, chemiluminescence, absorbance, reflectance, transmittance, birefringence, or refractive index (e.g., surface plasmon resonance, ellipsometry, a resonant mirror method, a grating coupler waveguide method, or interferometry). Optical methods include microscopy (both confocal and non-confocal), imaging methods, and non-imaging methods. Electrochemical methods include voltametry and amperometry methods. Radio frequency methods include multipolar resonance spectroscopy. Methods for performing these assays are readily known in the art. Useful assays include, for example, an enzyme immune assay (EIA) such as enzyme-linked immunosorbent assay (ELISA), a radioimmune assay (RIA), a Western blot assay, or a slot blot assay. These methods are also described in, e.g., Methods in Cell Biology: Antibodies in Cell Biology, volume 37 (Asai, ed. 1993); Basic and Clinical Immunology (Stites & Terr, eds., 7th ed. 1991); and Harlow & Lane, supra. In preferred embodiments, H2AX is detected after the protein binds to an anti-H2AX antibody and includes detection of fluorescence.
- Throughout the assays, incubation and/or washing steps may be required after each combination of reagents. Incubation steps can vary from about 5 seconds to several hours, preferably from about 5 minutes to about 24 hours. However, the incubation time will depend upon the assay format, marker, volume of solution, concentrations, and the like. Usually the assays will be carried out at ambient temperature, although they can be conducted over a range of temperatures, such as 10° C. to 40° C.
- Immunoassays can be used to determine the presence or absence of a marker in a sample as well as the quantity of a marker in a sample. The amount of an H2AX/anti-H2AX complex can be determined by comparing to a standard. A standard can be, e.g., a known compound or another protein known to be present in a sample. As noted above, the test amount of H2AX need not be measured in absolute units, as long as the unit of measurement can be compared to a control.
- The methods include detecting the expression level of microvesicle-associated H2AX in a biological sample from the test subject. The biological sample may be any sample from the body of the test subject that contains microvesicles. In preferred embodiments, the biological sample is a bodily fluid. As used herein, a “bodily fluid” refers to a sample of fluid isolated from anywhere in the body of the test subject, preferably a peripheral location, including but not limited to, for example, blood, plasma, serum, urine, sputum, spinal fluid, pleural fluid, nipple aspirates, lymph fluid, respiratory droplets, intestinal, and genitourinary tracts, tears, saliva, breast milk, fluid from the lymphatic system, semen, cerebrospinal fluid, intra-organ system fluid, ascitic fluid, tumor cyst fluid, synovial fluid, amniotic fluid, ocular fluid, ascites, bronchoalveolar lavage, and combinations thereof. In particularly preferred embodiments, the biological sample is blood. If the sample is blood, is it preferably centrifuged to remove cellular material and debris such that a plasma fraction is generated.
- In especially preferred embodiments, the biological sample includes, but is not limited to, plasma, serum, cerebrospinal fluid, urine, tears, milk, lymph fluid, synovial fluid, bronchoalveolar lavage, amniotic fluid, saliva, ocular fluid, ascites, and respiratory droplets.
- The H2AX detected in the methods are associated with microvesicles present in the biological sample. The microvesicles may be derived from endosomes (exosomes) or from the plasma membrane (shedding vesicles). The microvesicles may also be, for example, apoptotic bodies, prostasomes, P2 and P4 particles, or outer membrane vesicles (OMVs). The 1H2AX associated with the microvesicles may be membrane proteins or cytosolic proteins.
- The methods may include a step of isolating microvesicles from the biological sample prior to detecting the expression level of H2AX. Various different populations of microvesicles may be isolated. For example, when the methods relate to detection of the expression level of H2AX expressed by all tissues, the entire population of microvesicles is isolated. When the methods relate to detection of the expression level of expressed by multiple tissues, a specific sub-population of microvesicles derived from these tissues is isolated. When the methods relate to detection of the expression level of protein biomarkers expressed by a single tissue, microvesicles derived from that specific tissue are isolated. In preferred embodiments, microvesicles from various tissues are isolated by contacting microvesicles with a tissue-specific reagent.
- The entire population of microvesicles may be isolated according to any methods known to one of skill in the art (see, for example, Cocucci et al.,
Traffic 8, 2007: 742-757; Simpson et al.,Proteomics 8, 2008: 4083-4099). In certain embodiments, isolating microvesicles involves centrifugation. For example, serial centrifugation may be used to remove cells and debris, and microvesicles may be pelleted using sedimentation at 60-100,000×g for 1 hour or longer. Additional methods of differential centrifugation are described in Raposo et al., J Exp Med 183, 1996: 1161-72. In other embodiments, techniques such as filtration, sucrose density gradients, organelle electrophoresis, anion exchange and/or gel permeation chromatography, magnetic activated cell sorting (MACS), nanomembrane ultrafiltration concentration, and microchips with microfluidic technology may be used to isolate microvesicles. For example, large cell debris may be removed by filtration with a 0.22 m or a 0.1 m filter. Microvesicles may be isolated by passing the biological sample through a filter having an average pore diameter of between 0.01 m and about 0.15 μm. Linear sucrose gradients (2.0-0.25 M sucrose), or a combination of ultrafiltration (500 K membrane) and ultracentrifugation into a 30% sucrose/deuterium oxide (98%) cushion (density, 1.210 g/cm3) may also be used. Various methods for the isolation of microvesicles can be found, for example, in U.S. Pat. Nos. 6,899,863, 6,812,023, Taylor and Gercel-Taylor, Gynecol Oncol 110, 2008: 13-21, Cheruvanky et al., Am J Physiol Renal Physiol 292, 2007: F1657-61, and Nagrath et al., Nature 450, 2007: 1235-9. - In preferred embodiments, isolation of microvesicles is accomplished using affinity capture methods. Preferably, these affinity methods are immunoaffinity methods, but in certain embodiments, such methods employ other reagents which bind specifically to H2AX. Such methods can be a step in other methods prior to detection of H2AX described above.
- As a first step, the entire population of microvesicles may be isolated by contacting biological samples containing microvesicles with a reagent specific to a protein commonly found on the surface of all microvesicles regardless of origin (i.e., microvesicle-specific reagents). In certain embodiments, the reagents are specific to the following proteins: membrane adhesion proteins (integrins), membrane transport/trafficking proteins (annexins and Rab proteins, such as Rab guanosine triphosphatase), cytoskeletal components (actin, tubulin, ERM proteins, lysosomal markers, and tetraspanin proteins, such as CD9, CD63, CD81, and CD82), antigen presenting proteins (HLA class I and II), death receptors, cytokines and cognate receptors (TNF, TNFR1, and TGF-β), iron transport proteins, enzymes (enolase), cytosolic proteins (Hsc73 and Hsc90), subunits of trimeric G proteins, Tsg101, milk-fat globule (MFG)-E8, lactadherin, MHC class I molecules, heat shock proteins (Hsp70 and Hsp90), drug transporter proteins, or signal transduction proteins. In certain embodiments, reagents are specific to microvesicles from specific cell types such as class II MHC and co-stimulatory molecules (CD86) from antigen-presenting cells, von Willebrand factor or CD41a (GPIIb) from platelets, TCR from T-cells, or perforin or granzyme from cytotoxic T cells (Caby el al., Inter Immunol 17(7); 879-887; 2005). Reagents specific for lipids on the surface of microvesicles may also be used. For example, in preferred embodiments, the immunoaffinity capture includes use of an anti-phosphatidylserine antibody which binds to microvesicles having phosphatidylserine molecules with the polar side of the molecule exposed on its outer surface. The antibody is preferably monoclonal, but can also be polyclonal. In other embodiments, the first step isolates a specific sub-population of microvesicles, for example, those derived from endosomes or those derived from plasma membrane using antibodies specific to these sub-populations.
- Alternatively, as a first step, microvesicles may first be contacted with a reagent which binds specifically to microvesicles which are derived from a cancerous cell (i.e., cancer-derived microvesicle-specific reagent). Such a reagent may be one that binds only to microvesicles derived from cancerous cells or one that binds to any composition, such as a microvesicle, which displays certain cancer-specific proteins on its surface. If the reagent is the latter, the methods described herein will also include a step for isolating microvesicles or distinguishing them from other compositions found in the samples. Exemplary cancer-derived microvesicle-specific reagents include antibodies specific to tumor cell surface proteins or tumor antigen proteins. In certain embodiments, these proteins include tumor surface antigens, tumor invasion-related proteins, angiogenesis proteins, immune-suppressing cytokines, integrin proteins, and proteases. In certain embodiments, these proteins include cancer-specific cell-surface proteins such as those listed below in Table 1. Several studies have identified proteins specific to microvesicles derived from various tumor types (see, for example, Bard, M P et al., Am J Respir Cell Mol Biol. 2004 31(1):114-21; Hegmans, J P et al., Am J Pathol. 2004; 164(5):1807-15; Mears, R et al., Proteomics. 2004; 4(12):4019-31; and Choi, D S et al., J Proteome Res. 2007; 6(12):4646-55). These antibodies are preferably monoclonal, but can also be polyclonal. In preferred embodiments, the cancer-derived microvesicle-specific reagent is a reagent specific for phosphatidylserine, EGFRvIII, IDH1, PDGFRalpha, VEGFR, or αv/βIII integrin.
-
TABLE 1 Cancer-Specific Markers Cancer-Specific Markers APC C18orf8 C6orf138 CD44 CDH1 CDH11 CDH6 CDKN2A CDON CEP76 CTNNA1 CTNNB1 DHH FAT FGF9 FIGF FKBP8 FLT1 FLT4 FN1 FXYD5 GLI1 GLI2 GLI3 GSK3B HHAT HHIP IFT52 IHH ITGA7 ITGB3 KDR KITLG LAMR1 MCAM MGAT5 MMP10 MMP11 MMP13 MMP2 MMP3 MMP7 MMP9 MTSS1 NF1 NF2 NPC1 NPC1L1 NRP1 NRP2 OTX2 PDGFC PGF PNN PTCH1 PTCH2 PTCHD1 PTCHD2 PTCHD3 RPSA SHH SIAH1 SMO SUFU SYK TGFB1 TIMP2 TIMP3 TIMP4 VEGF VEGFA VEGFB VEGFC - In other embodiments, the cancer-derived microvesicle-specific reagent only binds to cancer-derived microvesicles derived from certain tissue types. In this case, the cancer-derived microvesicle-specific reagent is also a tissue-specific reagent.
- Before, subsequent to, or at the same time as capture with a first microvesicle-specific or cancer-derived microvesicle-specific reagent, the microvesicles, either in isolated form or found in the biological sample, can be contacted with a tissue-specific reagent to isolate microvesicles derived from a specific tissue. Exemplary tissues of interest include brain, adrenal gland, endocrine gland, pituitary, hypothalamus, parathyroid, uterus, heart, blood vessel, stomach, trachea, pharynx, gums, hair, scalp, subcutaneous tissue, Fallopian tube, reproductive tract, urethra, skin, bone, stem cell, umbilical cord, placenta, lymphocyte, monocyte, macrophage, formed blood cell, smooth muscle, skeletal muscle, connective tissue, spinal cord, kidney, bladder, anus, bone, breast, prostate, lung, cervix, colon, rectum, uterus, esophagus, skin, liver, pharynx, mouth, neck, ovary, pancreas, lung, eye, intestine, mouth, thyroid, GI tract, and endometrium.
- In certain embodiments, there is a third step of contacting the microvesicles with an organelle-specific reagent and isolating the microvesicles derived from organelles of cells in a specific tissue. Particular organelles of interest include plasma membrane, peroxisome, smooth ER, rough ER, lysosome, mitochondria, and nucleus.
- In some embodiments, each step is performed using multiple microvesicle-specific, cancer-derived microvesicle-specific, or tissue-specific reagents.
- In preferred embodiments, an anti-tenascin-C specific antibody is used to isolate microvesicles from brain tissue. In other preferred embodiments, microvesicles derived from certain tissues are isolated using antibodies to tissue markers known to those of skill in the art. For example, markers for brain tissue include VLP-1, synaptosomal-associated protein, GAD67, myelin-associated oligodendrocyte basic protein, synaptotagmin I,
tubulin β 4, zygin, glycine receptor β,protein 1 kinase C and casein kinase substrate inneurons 1, internexin neuronal intermediate filament protein a, neuroserpin,synaptobrevin 2, or neurogranin (Laterza et al.; Clin Chem 52:9; 1713-21; 2006). - In related embodiments, subsequent to capture with a first microvesicle-specific/cancer-derived microvesicle-specific reagent, the entire population of microvesicles is contacted with an reagent which binds to microvesicles derived from multiple tissue types rather than one that binds microvesicles derived from a specific tissue.
- In preferred methods for isolating microvesicles derived from specific tissue(s), the method includes contacting a biological sample with an reagent specific for microvesicles, preferably a reagent specific for phosphatidylserine, wherein the biological sample includes microvesicles and the reagent binds to microvesicles; contacting the microvesicles with a tissue-specific reagent and then isolating the microvesicles derived from the tissue(s).
- In particularly preferred embodiments, methods for isolating microvesicles derived from brain cancer tissue from blood include the steps of providing blood; providing plasma by centrifuging the blood; contacting plasma with an anti-phosphatidylserine antibody in a physiological buffer, wherein the anti-phosphatidylserine antibody binds to microvesicles; isolating microvesicles bound by the anti-phosphatidylserine antibody; contacting the microvesicles with an anti-tenascin antibody; and isolating the microvesicles derived from brain cancer tissue. Preferably, the plasma is contacted with an anti-phosphatidylserine antibody for about 60 minutes and the microvesicles are isolated by changing the ionic strength of the physiological buffer.
- Contacting a biological sample with an microvesicle-specific reagent or cancer-derived microvesicle-specific reagent and contacting the microvesicles with a tissue-specific reagent may occur in a single step. Under such circumstances, the reagents may be coupled to the same solid support. Alternatively, the steps are performed sequentially. The biological sample is first contacted with a microvesicle-specific reagent/cancer-derived microvesicle-specific reagent and then contacted with a tissue-specific reagent, sometimes with an intervening step of isolating the microvesicles bound by a microvesicle-specific/cancer-derived microvesicle-specific reagent. The steps may also be reversed, such that biological sample is first contacted with a tissue-specific reagent and then a microvesicle-specific/cancer-derived microvesicle-specific reagent, sometimes with an intervening step of isolating a fraction bound by the tissue-specific reagent.
- Contacting the biological sample and the reagents occurs for a suitable incubation time which optimizes the efficiency of the microvesicle/tissue marker:reagent interaction. It is well within the competence of one of ordinary skill in the art to determine the particular conditions based on the disclosure herein. Typically, the biological sample and reagents are incubated together in a suitable buffer at physiological pH at a suitable temperature (e.g., about 4-37° C.), for a suitable time period (e.g., about 60 minutes to overnight) to allow the binding to occur.
- Once bound by reagent, microvesicles are isolated using standard methods known to those of skill in the art. For example, if the microvesicles are bound to an immunoaffinity resin, the resin is washed with physiological buffers, such as Tris-Acetate pH 7.6 to remove other unbound components of the biological sample and then eluted by changing the ionic strength of the buffer for the resin, for example, by gradually increasing the concentration of a salt, such as NaCl, CaCl2, KCl, MgCl2, or similar salts that cause the reagent to release the bound microvesicles. Sepharose 2B columns may also be used for size exclusion methodologies of isolating microvesicles (Taylor et al., 2012).
- The reagents are typically coupled to solid supports. A solid support, for purposes of the present disclosure, can be any material that is an insoluble matrix and can have a rigid or semi-rigid surface to an reagent can be linked or attached. Exemplary solid supports include, but are not limited to, substrates such as nitrocellulose, polyvinylchloride; polypropylene, polystyrene, latex, polycarbonate, nylon, dextran, chitin, sand, silica, pumice, agarose, cellulose, glass, metal, polyacrylamide, silicon, rubber, polysaccharides, polyvinyl fluoride, diazotized paper, activated beads, magnetically responsive beads, and any materials commonly used for solid phase synthesis, affinity separations, purifications, hybridization reactions, immunoassays and other such applications. The support can be particulate or can be in the form of a continuous surface and includes membranes, mesh, plates, pellets, slides, disks, capillaries, hollow fibers, needles, pins, chips, solid fibers, gels (e.g. silica gels) and beads, (e.g., pore-glass beads, silica gels, polystyrene beads optionally cross-linked with divinylbenzene, grafted co-poly beads, polyacrylamide beads, latex beads, dimethylacrylamide beads optionally crosslinked with N-N′-bis-acryloylethylenediamine, iron oxide magnetic beads, and glass particles coated with a hydrophobic polymer.
- Typically, the solid support is a bead or resin in a column configuration. In preferred immunoaffinity capture methods for isolating microvesicles of interest, the method includes providing a column, applying a biological sample suspected of containing one or more of the microvesicles of interest to bind to resins in the column, washing the column, eluting the resins and analyzing the eluant for the presence of the microvesicles of interest. More specifically, such methods can include loading the column with a predetermined amount of a biological sample suspected of containing the microvesicles of interest in either blood plasma or a physiological buffer; binding the microvesicles to the reagent on the column; loading the column with a wash solution, suspending the resin in the wash solution; removing the wash solution from the column; eluting the microvesicles in eluant; and analyzing the eluant for the presence of the microvesicles.
- In certain embodiments, it is preferred that that the column configuration used in such methods allows for suspension of the resin beads, such as a mobile bead column or other resin during washing. It has been discovered that such a column configuration results in significantly lower levels of background and hence more sensitive levels of quantitation and overall yield of the desired target.
- In certain embodiments, the column used in such methods includes a lower end including an outflow opening; a lower porous support; a layer of resin on the lower porous support, the resin having specific affinity for all microvesicles or tissue-specific microvesicles; an upper porous support; and an upper end including an inflow opening; wherein the resin between the lower porous support and the upper porous support is structured and arranged to permit removal of the upper porous support from the column without substantial removal of resin.
- In other embodiments, the resin is fixed between two semi-porous frits such that the resin beads may be suspended and such that the upper frit may be removed during washing of the resin to remove background compounds.
- The volume of the resin in the column can vary but is typically less than the total packed volume of the column between the lower porous support and the upper porous support. Preferably, the volume of the resin in the column is no greater than 50%, more preferably no greater than 40%, even more preferably no greater than 30%, still more preferably no greater than 25%, and still more preferably no greater than 20% of the total packed volume of the column between the lower porous support and the upper porous support.
- Described herein are methods of monitoring genotoxic stress due to cancer treatment in a test subject, specifically by detecting the expression level of microvesicle-associated H2AX.
- In certain embodiments, methods include comparing the expression level of H2AX in the biological sample from the test subject with the expression level of H2AX in a biological sample from a control subject that is not given the cancer treatment. The expression levels from biological samples from the plurality of control subjects may be simultaneously obtained with the test subject expression levels or may constitute a set of numerical values stored on a computer or on computer readable medium. In preferred embodiments, the control subjects are of the same sex and of a similar age as the test subject. Control subjects may also be of a similar racial background as the test subject. Preferably, biological samples taken from the test subject and from the plurality of control subjects are of the same type, e.g., blood samples.
- Comparison of the expression levels of the one or more microvesicle-associated H2AX in biological samples from the test subject and from a plurality of control subjects may be performed manually or automatically by a computer program. The expression level of H2AX in the biological sample from the test subject may be compared individually to the expression level of the microvesicle-associated H2AX from biological samples in each control subject, or the expression level of microvesicle-associated H2AX in the biological sample from the test subject may be compared to an average of the expression levels from biological samples from the plurality of control subjects. In certain embodiments, the values for the expression levels of H2AX in biological samples from both the test subject and the plurality of control subjects may be transformed. For example, the expression levels may be transformed by taking the logarithm of the value. Moreover, the expression levels may be normalized by, for example, dividing by the median expression level among all of the samples.
- In certain embodiments, the expression level of microvesicle-associated H2AX in the biological sample from the test subject is increased relative to the expression level of the one or more microvesicle-associated H2AX in biological samples from a plurality of control subjects. In other embodiments, the expression level of microvesicle-associated H2AX in the biological sample from the test subject is decreased relative to the expression level of microvesicle-associated H2AX in biological samples from a plurality of control subjects.
- The steps of the method may be practiced by either one or more than one entity. An entity may be, for example, a person, a group of people, an institution, or a business.
- According to certain aspects, the steps required to practice the method are practiced by one entity. In certain embodiments, a single entity may detect the expression levels of microvesicle-associated H2AX in a biological sample from the test subject and then monitor the cancer treatment or determine the efficacy of cancer treatment. This entity may be, for example, a doctor or a clinician. This entity may also be an institution, such as a hospital or a doctor's office, where all steps of the methods are performed by employees of the institution.
- In other embodiments, a single entity may detect the expression levels of microvesicle-associated H2AX in a biological sample from the test subject and communicate the expression levels to a different entity that then monitors the cancer treatment or determines the efficacy of the cancer treatment. In these embodiments, the single entity performing the steps of detecting and communicating may be, for example, a clinic or a lab technician.
- More than One Entity
- According to other aspects, the steps required to practice the method may be performed by more than one entity. One entity may detect the expression levels of microvesicle-associated H2AX in a biological sample from the test subject, whereas a different entity may monitor the cancer treatment or determine the efficacy of the cancer treatment. For example, a lab technician at a clinic may detect the expression levels of H2AX in a biological sample from the test subject, and a doctor at a hospital may determine the efficacy of the cancer treatment.
- Communication between Entities
- Communication between entities in practicing methods may occur by any means used in the art. Typically, information communicated between entities will be in the form of a report. In certain embodiments, a first entity may obtain expression levels of microvesicle-associated H2AX in a biological sample from the test subject from a second entity that detects the expression levels of microvesicle-associated H2AX in a biological sample from the test subject. The first entity may obtain the expression levels from the second entity directly or indirectly. For example, the first entity may obtain a paper or electronic report of the expression levels directly from the second or different entity. In another example, the first entity may obtain an electronic report of the expression levels on a network to which the second entity has uploaded the report. In yet another example, the first entity may obtain the expression levels from a third entity that has prepared a report from the detections by the second entity.
- In other embodiments, a first entity may detect the expression levels of microvesicle-associated H2AX in a biological sample from the test subject and communicate the expression levels to a second or different entity that then monitors the cancer treatment or determines the efficacy of the cancer treatment. The first entity may communicate the expression levels to the second entity directly or indirectly. For example, the first entity may prepare a report with the expression levels and give the report to the second entity manually or electronically. In another example, the first entity may upload the expression levels to a network from which the second entity can obtain the levels. In yet another example, the first entity may communicate the expression levels to a third entity that prepares a report for use by the second entity.
- Methods described herein may be useful for clinical trials involving cancer. Typically, for their use in clinical trials, the steps required to achieve the objects of the invention will be practiced by more than one entity. For example, multiple entities in different locations, such as clinics in different cities, may detect the expression levels of the one or more microvesicle-associated proteins in a biological sample from the test subject and communicate the expression levels to a different entity, such as a group of doctors directing the clinical trial, who then determine the efficacy of the cancer treatment. In certain embodiments, the multiple entities may use a third entity that prepares and communicates reports of the expression levels to the different entity that determines the efficacy of the cancer treatment. Clinical trials involving the described methods may be useful for evaluating effectiveness of new drugs and treatments for cancer or for evaluating the effects of various clinical parameters on cancer and its progression.
- Also provided are reagents and kits thereof for practicing one or more of the above-described methods. The subject reagents and kits thereof may vary greatly. Reagents of interest include reagents specifically designed for use in detection of the above-described expression levels of microvesicle-associated H2AX.
- One type of such reagent is an array or kit of antibodies that bind to a biomarker cluster of interest. A variety of different array formats are known in the art, with a wide variety of different probe structures, substrate compositions, and attachment technologies. Representative array or kit compositions of interest include or consist of reagents for quantitation of at least 1 microvesicle-associated protein, such as H2AX.
- The kits may further include a software package for statistical analysis of one or more phenotypes, and may include a reference database for calculating the probability of classification. The kit may include reagents employed in the various methods, such as devices for withdrawing and handling blood samples, second stage antibodies, ELISA reagents, tubes, spin columns, and the like.
- In addition to the above components, the subject kits will further include instructions for practicing the subject methods. These instructions may be present in the subject kits in a variety of forms, one or more of which may be present in the kit. One form in which these instructions may be present is as printed information on a suitable medium or substrate, e.g., a piece or pieces of paper on which the information is printed, in the packaging of the kit, in a package insert, etc. Yet another means would be a computer-readable medium, e.g., diskette, CD, etc., on which the information has been recorded. Yet another means that may be present is a website address which may be used via the internet to access the information at a removed site. Any convenient means may be present in the kits.
- The following examples are offered for illustrative purposes and to aid one of skill in better understanding the various embodiments of the disclosure. The following examples are not intended to limit the scope of the present disclosure in any way.
- The following example demonstrates that microvesicle-derived unphosphorylated H2AX and microvesicle-derived γH2AX are markers of genotoxic stress in a cell. Treatment of U87 brain cancer cells with the DNA alkylating agent temozolomide (TMZ) induced increased abundance of H2AX and γH2AX proteins in microvesicles derived from the U87 cells.
- U87 MG (ATCC® HTB14™) cell cultures represent glioblastoma multiforme (GBM). An Integra CELLine Bioreactors (Hudson, N.H.) was seeded from T-75 cultures of U87 into the 15 ml lower chamber, separated by a 10 kDa MWCO filter from a 500 ml upper reservoir chamber. After growth was established in the lower chamber containing exosome free fetal bovine serum (Exo-FBS Systems Biosciences, Mountain View Calif.), supernatant samples were recovered on a weekly basis. Upper chambers of the bioreactors were replenished with normal fetal serum-containing medium. The cultures used were between 4 and 5 months old and were monitored for continued robust health.
- On
day 1 of the study, the Integra bioreactor was provided with normal Eagles minimal essential medium (EMEM) supplemented with exosome-free fetal bovine serum FBS. Additionally fresh media was added to the upper chamber. Supernatant samples were taken at 2, 4, 6, and 24 hours after addition of fresh medium, mixed with protease inhibitor and Venceremin peptide reagent (New England Peptide, Gardner, Mass.) for incubation at 4° C. - Culture supernatants were collected at 24 hours. Fresh medium was added to both the lower and upper chamber adjusted to 100 μm TMZ was added (day 2) and supernatant samples taken as indicated above. The process was repeated at 48 hours with the exception that fresh media had been adjusted to 300 μm TMZ (day 3). The final collection of lower chamber supernatant occurred at 72 h.
- Microvesicles in the conditioned media were recovered from culture supernatants using one of the Venceremin peptides (New England Peptide, Gardner Mass.). Venceremins were originally identified as ligands with strong avidity for heat shock proteins, particularly HSP90 and of variable affinity to isoforms of HSP70, HSP60 and other chaperone proteins. Microvesicles from pathologically affected cells, particularly cancer, display HSPs on the external surface. To recover microvesicles, the Venceremin peptide Vn96reverse, referred to as Heladonin (Hdn: H2N-LKLFEGLTLAGWSFRSLSLGRGKGQSP-OH), was used. The Integra bioreactor lower chamber supernatant samples (2 mls) were mixed with 101 of protease inhibitor and 50 μg of Hdn peptide stock solution. Microvesicles were prepared from Bioreactor supernatant samples taken at 2, 4, 6 and 24 hours after addition of fresh medium and placed at 4° C.
- All samples were incubated for at least 18 h. The samples were processed by centrifugation (4500 g) washing in 1 ml of PBS and repeat centrifugation. The presence of U87 microvesicles in material pelleted from the lower chamber of the cell cultures was determined by Western blotting.
- Cell Culture Media
- Exosome-free fetal bovine serum (FBS) supplement was purchased from Exo-FBS Systems Biosciences, Mountain View Calif. Eagles minimal essential medium (EMEM) supplied by ATCC Cat #30-2003. Complete 10% fetal bovine serum 90% EMEM was placed in the upper reservoir chamber of the CELLine Bioreactor. Prior to introduction of U87 cells into the bioreactor, the bioreactor was provided with Eagle's minimum essential medium+100 U/ml penicillin+100 μg/ml streptomycin (EMEM)+10% exosome-free fetal bovine serum FBS. After U87 cell introduction into the bioreactor, the bioreactor was cultured at 37° C. in a 5% carbon dioxide atmosphere. Upper chamber contains EMEM supplemented regular fetal bovine serum. A control bioreactor containing 15 mls of EMEM+Exo-free Medium placed at 37° C. was used. 2mls were taken from the controls each day and replaced with fresh medium.
- Temozolomide (TMZ) Preparation
- The MW of TMZ is 194.151 g/mol. 100 mg TMZ was dissolved in 5 ml of DMSO (20 mg/ml TMZ), which is equivalent to 20 μg/μl TMZ (257 mM). The stock solution of TMZ was used to provide TMZ at designated concentrations in the culture media of the bioreactor.
-
Day 1 Protocol-Introduction of Fresh Serum-EMEM to Bioreactor Culture (No TMZ) - The culture received fresh SBI Exosome-free serum supplemented media in lower chamber and regular FBS-supplemented media in the upper chamber and placed in a 37° C. incubator. At 2, 4 and 6 h the bioreactor was retrieved from the incubator and rocked gently for 1 min. 2 mls of media were removed from the lower cell chamber and transferred to 2.0 ml HANDEE microcentrifuge tube (PIERCE Rockland II) containing 5 ul of protease inhibitor (Cocktail III, EMD Merck Millipore). 2 mls of fresh media was added to upper chamber to compensate for removal. The retrieved volumes of supernatant (SN) were centrifuged at 17000 g for 5 m at 4° C. to pellet microparticulates and cell debris. 1.8 ml supernatant was transferred to a new tube taking care to avoid any pelleted material. The SN was mixed with 10 μl of Hdn peptide stock solution and incubated at 4° C. overnight for microvesicle recovery. The cell and microparticle pellet (17000 g) was stored at −80° C.
-
Day 2 Protocol-Recovery of Microvesicle Population and Introduction of New Media Containing 100 μM TMZ - After 24 h the bioreactor flask was retrieved from incubators and rocked gently for 5 m. All of the culture medium was retrieved from the lower cell chamber and immediately replaced with fresh EMEM with Exo-FBS containing 100 μM TMZ stock solution. 100 μM TMZ was also added to the upper chamber.
- For the 24 hour microvesicle sample, 2 ml samples of SN were transferred to HANDEE tubes containing 5 μl of protease inhibitor as for the 2, 4 and 6 h samples and placed at 4° C. All remaining culture SN was frozen at −80° C. The cell free solutions serving as negative controls were also processed in an identical manner.
-
Day 3 Protocol-Recovery of Microvesicle Population and Introduction of New Media Containing 300 μM TMZ - Replacement of media and processing of samples for the collection of microvesicles was conducted in the same manner as
day 2 with the exception that serum-supplemented EMEM was adjusted to 300 μM TMZ in both upper and lower chambers of the CELLine Bioreactor. -
Day 4 Protocol-Final Collection of Culture Supernatant - Replacement of media and processing of samples for the collection of microvesicles was conducted in the same manner as
day 2 with the exception that no further addition of TMZ was given to the cultures and the collection of lower chamber supernatant was considered the end of the experiment. The accumulated microvesicle samples were stored at 4° C. for a minimum of 18 h for processing together onday 5 in preparation for gel electrophoresis. - Preparation of Microvesicles
- All SN samples stored at 4° C. with Hdn peptide and protease inhibitor were centrifuged at 4500 g for 5 m at 4° C. The SNs were utilized to isolate the microvesicle pellets. Protein pellets were resuspended in 1 ml of PBS by vortexing and returned to the microcentrifuge for 5 m at 4500 g at 4° C. Protein pellets were prepared for electrophoresis by resuspension in a variant of Laemmli SDS buffer as previously described (Wubbolts et al., 2003). The premixed 4×XT loading buffer (Bio-Rad) was adjusted to 4M urea, 25 mM TCEP (reducing agent; PIERCE) and 5 μl/ml of protease inhibitor (Cocktail III EMD Milipore). The electrophoresis sample/loading buffer was referred to as “USB” for urea sample buffer. Samples were incubated at 95° C. in a dry-heating block for 5 minutes, vortexed vigorously and given a 30 s spin in a microcentrifuge to bring down droplets and condensation.
- Electrophoresis and Blotting Conditions
- Frozen samples in SDS/Urea electrophoresis buffer were incubated at 95° C. for 30 seconds, vortexed and microfuged briefly. 25 μl volumes were applied to 10% XT Bis-Tris Criterion precast midi gels in XT-MES running buffer (all products Bio-Rad Hercules Calif.). Gels were run in Criterion modules (Bio-Rad) for approximately 55 minutes at 150 V. After electrophoresis was complete, the gels were rinsed in Towbin transfer buffer and layered onto supported nitrocellulose, blotting pads and paper (BioRad), all assembled into a blotting cartridge for insertion in the Criterion blotting module. The blotting module contained pre-chilled Towbin transfer buffer and an ice pack. Blotting was considered complete by running at 90V for 30 m. The blot was rinsed in distilled deionised water and processed with the Pierce reversible protein stain kit. The images were captured using a Bio-Rad Chemi-Doc using white light mode and allowed to dry.
- Antibody Reactivity and Image Generation
- The blots were destained to clear background by rehydration in ddH2O and use of destaining reagent (PIERCE). The blots were blocked for 30 minutes in 5% low-fat skim milk powder dissolved in phosphate buffered saline adjusted to 0.075% Tween 20 (TPBS).
- The blots were cut longitudinally at the 37 kDa marker (i.e. perpendicular to the direction of electrophoresis) to allow for the same samples to be probed for low molecular weight (bottom) and high molecular weight proteins (top). In this instance the target was gamma γH2AX (˜17 kDa Anti-phospho-Histone H2A.X_Ser139: Millipore MABE205). After reactivity to these antibodies had been recorded, the same blots were incubated with a secondary sequence of H2AX (i.e. unphosphorylated H2AX anti-Histone H2A.X: Millipore 07-627).
- Primary antibody was mixed with 3% milk dissolved in TPBS at a 1:2000 dilution and the blot incubated for 60 minutes, washed 4 times with an equal volume of TPBS, incubated by a 1:2000 dilution of horse-radish peroxidase (HRP) secondary antibody, washed 4 times for 10 minutes with TPBS. All incubations rocking and washes were conducted automatically with a Freedom Rocker device (Next Advance, Averil Park N.Y.). The antibody-probed and TPBS washed blot halves were covered with 1 ml of Super Signal West Dura HRP substrate (PIERCE), covered with cling film and imaged using the Chemi-Doc at exposures between 2 s and 60 s depending on the signal intensity.
- Growth Conditions for U87 Cultures Used in Subcellular Protein Analysis
- U87 cell cultures were grown as a monolayer in T-75 flasks (Corning, 75 cm2, ultra low attachment surface).
Flask 1 was designated as a control flask, whileFlasks - Subcellular Fractionation and Compartment Isolation
- Control and TMZ-treated U87 cells were processed into subcellular fractions using the sub-cellular proteome extraction kit (S-PEK, EMD Milipore) according to manufacturer instructions using differential detergent extraction with four extraction buffers to isolate proteins enriched in various cellular compartments. Various buffers were used in the extraction process to enrich for proteins in specified compartments as follows: from the cytoplasmic compartment in Extraction buffer 1 (EB1); enriched in membrane-associated proteins, Extraction buffer 2 (EB2); enriched in nucleus-associated proteins, Extraction buffer 3 (EB3) or enriched in cytoskeletal proteins, Extraction buffer 4 (EB4). All blots on cellular compartment-extracted proteins were conducted as described for microvesicle-isolated proteins.
- H2AX and γH2AX are Markers of Genotoxic Stress
- Table 2 illustrates the microvesicle samples analyzed in the blot analyses and the corresponding lanes for the respective samples, the results of which are depicted in
FIG. 1 andFIG. 2A, 2B . -
TABLE 2 Identification of Microvesicle Samples in the Specified Blot Lanes U87 Media and MCVS Harvested from Lane # Exosome Free Culture Media 1 5X dilution of MW standard 2 Controls + (SBI) 2 hours 3 Controls + (SBI) 4 hours 4 Controls + (SBI) 6 hours 5 Controls + (SBI) 24 hours 6 (SBI + 100 μm TMZ) 2 hours 7 (SBI + 100 μm TMZ) 4 hours 8 (SBI + 100 μm TMZ) 6 hours 9 (SBI + 100 μm TMZ) 24 hours 10 (SBI + 300 μm TMZ) 2 hours 11 (SBI + 300 μm TMZ) 4 hours 12 (SBI + 300 μm TMZ) 6 hours 13 (SBI + 300 μm TMZ) 24 hours 14 Blank 15 Control SBI Media 016 Control SBI Media 117 Control SBI Media 218 Blank - All samples appeared closely matched in overall intensity of total protein profile, with subtle variation in protein intensity at higher (e.g. ˜250 kDa) and lower (10-25 kDa) molecular weight (
FIG. 1 , lanes 2-13). Protein was also recovered from the exosome-free serum product in the absence of cell material (FIG. 1 , lanes 15-17; SBI-EFM). - For γH2AX (
FIG. 2A ), a band migrating between the 15 and 20 kDa marker was clearly observed at 2, 6 and 24 h after medium replacement, with only a thin band seen at 4 h (FIG. 2A ,lanes day 3 following addition of 300 uM temozolomide (TMZ) to the culture media. This study therefore presents the first recorded observation of γH2AX, a nuclear biomarker reflecting alkylation of DNA, captured in shed microvesicle material. Without wishing to be bound by theory, it is believed that the identification of γH2AX on the first day, in the absence of the DNA damaging agent (TMZ), supports the observation that the U87 phenotype is associated with genomic instability due to the observed release of γH2AX in microvesicles. After 3 days of exposure to TMZ, γH2AX became consistent in intensity and was more abundant following addition of TMZ to the culture media. This latter observation indicates that prolonged exposure to TMZ increases the probability that γH2AX will be incorporated into microvesicles. γH2AX in microvesicles may thus be used as an indicator of phenotypic genomic instability and increased DNA damage due to drug or radiation exposure. - For H2AX (
FIG. 2B ), the antibody to unphosphorylated H2AX was used secondarily to the same blot probed for γH2AX. It was observed that the protein expression of H2AX, even in the presence of TMZ, was similar to that observed for γH2AX. H2AX in microvesicles may thus be used as an indicator of phenotypic genomic instability and increased DNA damage due to drug or radiation exposure. - H2AX and γH2AX are Nuclear Proteins
- Table 3 illustrates the subcellular compartment samples analyzed in the blot analyses and the corresponding lanes for the respective samples, the results of which are depicted in
FIG. 3 . -
TABLE 3 Identification of Subcellular Compartment Samples in the Specified Blot Lanes Lane # T-75 Monolayer Flasks 1 5X dilution of MW standard 2 Blank 3 0 μM TMZ, EB1 4 0 μM TMZ, EB2 5 0 μM TMZ, EB3 6 0 μM TMZ, EB4 7 Blank 8 50 μM TMZ, EB1 9 50 μM TMZ, EB2 10 50 μM TMZ, EB3 11 50 μM TMZ, EB4 12 Blank 13 100 μM TMZ, EB1 14 100 μM TMZ, EB2 15 100 μM TMZ, EB3 16 100 μM TMZ, EB4 17 5X dilution of MW standard 18 U87 control - As can be seen in
FIG. 3A , γH2AX protein could only be detected in nuclear fractions of U87 protein extracts from whole cells, as represented by the single detected band marked with an arrow. γH2AX protein also began to accumulate only in the nucleus following application of TMZ to the cell culture. Similarly, and as can be seen inFIG. 3B , H2AX protein could only be detected in nuclear fractions of U87 protein extracts from whole cells (large arrow). A smaller protein was also detected in nuclear extracts (small arrow) with an H2AX antibody, possibly representing a degradation product or fragment of H2AX. - In summary, both γH2AX and H2AX proteins could only be detected in nuclear fractions of U87 cells, as these proteins were absent from protein extracts enriched for cytoplasmic, membrane-associated, and cytoskeletal proteins. These data confirm that both γH2AX and H2AX are nuclear-localized proteins and confirm that the source of the exosomal signal for γH2AX appears not to be derived from cytoplasmic or membrane bound protein.
- The following example demonstrates that microvesicle-derived unphosphorylated H2AX and microvesicle-derived γH2AX, which are both histone proteins, are relevant tumor markers. These protein markers were found to be associated with microvesicles shed from various tumor or tumor-like cell lines, including a cervical cancer model cell line (HELA), a glioma model cell line (U87), and a model highly proliferative renal cell line (HEK293T).
- Overview of Microvesicles Harvested from Tumor Cell Lines-Experimental Outline
- HELA (ATCC® ccl-2™), U87 (ATCC® HTB14™), and HEK293T (ATCC® CRL-1573™) cell cultures were grown in Integra CELLine Bioreactors (Hudson, N.H.) after seeding from T-75 cultures into the 15 ml lower chamber, separated by a 10 kDa MWCO filter from a 500 ml upper reservoir chamber. After growth was established in the lower chamber containing exosome free fetal bovine serum (Exo-FBS Systems Biosciences, Mountain View Calif.), supernatant samples were recovered on a weekly basis. Upper chambers of the bioreactors were replenished with normal fetal serum-containing medium. The cultures used were between 4 and 5 months old and were monitored for continued robust health.
- Microvesicles in the conditioned media were recovered from culture supernatants using Venceremin peptides (Vn96, New England Peptide, Gardner Mass.) in conjunction with a variety of wash buffers for the disaggregation of microvesicles prior to use of Vn96. Microvesicles from these cells were harvested in the conditioned media from the Integra bioreactor lower chamber and supernatant samples (2 mls) were mixed with 1 Oi of protease inhibitor and 50 μg of Vn96 peptide stock solution. Microvesicles were prepared from Bioreactor supernatant samples taken at 2, 4, 6 and 24 hours after addition of fresh medium and placed at 4° C.
- Cell Culture Medium
- Exosome-free fetal bovine serum (FBS) supplement was purchased from Exo-FBS Systems Biosciences, Mountain View Calif. Eagles minimal essential medium (EMEM) supplied by ATCC Cat #30-2003. Complete 10% fetal bovine serum 90% EMEM was placed in the upper reservoir chamber of the CELLine Bioreactor. Prior to introduction of cells into the bioreactor, the bioreactor was provided with Eagle's minimum essential medium+100 U/ml penicillin+100 μg/ml streptomycin (EMEM)+10% exosome-free fetal bovine serum FBS. After cells were introduced into the bioreactor, the bioreactor was cultured at 37° C. in a 5% carbon dioxide atmosphere. Upper chamber contains EMEM supplemented regular fetal bovine serum.
- Preparation of Microvesicles
- Raw Stock Solutions containing U87, HELA, or HEK293T (293T) bioreactor culture medium were concentrated by
VivaSpin 1 million Dalton molecular weight cut off (MWCO) spin filters and resuspended in 50 mM amino acid solution (Stock B) or 5% detergent (Stock D). These solutions were prepared for electrophoresis directly by adding 50 μl of 3× urea SDS sample buffer (USB) to 100 μl of the stock solutions. After heating at 95° C., 15 μl were loaded. Samples of Stock B and Stock D can be seen inlanes FIG. 4 ). - Peptide recovered microvesicles using Vn96 (microvesicle samples) were prepared by incubating 1.8 ml volumes of CELLiNE Integra bioreactor culture media from U87, HELA, or 293T cells with 50 μg of peptide overnight at 4° C. After incubation of the mixtures were centrifuged at 4500 g washed by resuspending in 500 μl of Stock B and re-pelleted by centrifugation. The supernatant was removed and the pellet resuspended in 200 μl of 1× urea SDS sample buffer (USB). 15 μl were loaded to the gel. U87, HELA and 293T microvesicle samples are shown in lanes 4-6 of
FIG. 4 . Other samples inFIG. 4 were collected by PD-10 size exclusion chromatography (SEC) using 2% agarose beads and selected buffers. - 1 ml sample volumes and 1 ml eluate fractions were collected by gel filtration procedure PD-10 SEC as discussed herein to form the contents of peak 1 (
fractions fractions VivaSpin 2ml 1 million Dalton molecular weight cut off (MWCO) spin filter;fractions fractions peak 1, were pooled and resuspended in 1 ml of water. The remaining 500 μl was centrifuged to minimum volume and resuspended in 150 μl of 1× urea SDS sample buffer (USB). 15 μl were loaded to the gel. The concentrated pooledpeak 1 fractions were prepared from U87 bioreactor culture medium that had been concentrated byVivaSpin 1 million Dalton molecular weight cut off (MWCO) spin filters and resuspended in AB Serum (Stock A) as indicated above following the PD-10 fractionation into 1ml volumes fractions - Mass Spectrometry Protein Analysis
- U87 preparations were resuspended into Serum A/B and microvesicles isolated using gel filtration. Microvesicle particles were isolated and subjected to protein isolation and tryptic digest. Microvesicle fractions were run on an on 8%, 10%, and 12% T columns using the GELFrEE system (Protein Discovery), collecting 12 fractions per column. GELFrEE fractions were processed by acetone precipitation for SDS removal according to the method described in Botelho et al. (2010). Fractions were analyzed via bottom-up LC-MS/MS on a Thermo LTQ mass spectrometer and identified using Scaffold (Proteome Software) and Bioworks, and quantified via spectral counting according to Yates et al. (2004).
- Electrophoresis and Blotting Conditions
- Frozen samples in SDS/Urea electrophoresis buffer were incubated at 95° C. for 30 seconds, vortexed and microfuged briefly. 25 μl volumes were applied to 10% XT Bis-Tris Criterion precast midi gels in XT-MES running buffer (all products Bio-Rad Hercules Calif.). Gels were run in Criterion modules (Bio-Rad) for approximately 55 minutes at 150 V. After electrophoresis was complete, the gels were rinsed in Towbin transfer buffer and layered onto supported nitrocellulose, blotting pads and paper (BioRad), all assembled into a blotting cartridge for insertion in the Criterion blotting module. The blotting module contained pre-chilled Towbin transfer buffer and an ice pack. Blotting was considered complete by running at 90V for 30 m. The blot was rinsed in distilled deionised water and processed with the Pierce reversible protein stain kit. The images were captured using a Bio-Rad Chemi-Doc using white light mode and allowed to dry.
- Antibody Reactivity and Image Generation
- The blots were destained to clear background by rehydration in ddH2O and use of destaining reagent (PIERCE). The blots were blocked for 30 minutes in 5% low-fat skim milk powder dissolved in phosphate buffered saline adjusted to 0.075% Tween 20 (TPBS).
- The blots were cut longitudinally at the 37 kDa marker (i.e. perpendicular to the direction of electrophoresis) to allow for the same samples to be probed for low molecular weight (bottom) and high molecular weight proteins (top). In this instance the target was gamma γH2AX (˜17 kDa Anti-phospho-Histone H2A.X_Ser139: Millipore MABE205). After reactivity to these antibodies had been recorded, the same blots were incubated with a secondary sequence of H2AX (i.e. unphosphorylated H2AX anti-Histone H2A.X: Millipore 07-627). In a separate series of gels, the blots were probed for the presence of pan Histones using the Anti-Histone H4 Antibody: Millipore 04-858.
- Primary antibody was mixed with 3% milk dissolved in TPBS at a 1:2000 dilution and the blot incubated for 60 minutes, washed 4 times with an equal volume of TPBS, incubated by a 1:2000 dilution of horse-radish peroxidase (HRP) secondary antibody, washed 4 times for 10 minutes with TPBS. All incubations rocking and washes were conducted automatically with a Freedom Rocker device (Next Advance, Averil Park N.Y.). The antibody-probed and TPBS washed blot halves were covered with 1 ml of Super Signal West Dura HRP substrate (PIERCE), covered with cling film and imaged using the Chemi-Doc at exposures between 2 s and 60 s depending on the signal intensity.
- Table 4 illustrates the microvesicle samples analyzed in the blot analyses and the corresponding lanes for the respective samples, the results of which are depicted in
FIG. 4 . -
TABLE 4 Microvesicle Samples in the Specified Blot Lanes Lane # Condition/Source of Protein 1 Molecular weight markers 2 U87 in 50 mM amino acid solution (Stock B) 3 U87 in 5% detergent (Stock D) 4 U87 microvesicle sample 5 HELA microvesicle sample 6 HEK293T microvesicle sample - The blots described above were probed to detect specific proteins in the various samples (See Table 4 and
FIG. 4 ). In all instances with the exception of CD63, the detection of all proteins was strongest in the peptide recovered microvesicle fractions (microvesicle samples). Antibodies to all histones (pan-histone), H2AX, and γH2AX were strongly represented in the microvesicle samples (lanes lanes 2 and 3), which were obtained from cell culture samples and not enriched for microvesicles. Histones are a surface feature of rapidly dividing cells, such as cancers. The data presented inFIG. 4 suggests that histones are incorporated into shed microvesicles from tumor cells. Without wishing to be bound by theory, it is also thought that, as histones may be part of nucleosomes, they may be shed from the cells in membranous form. The rich presence of histones in the tumor cell-derived microvesicle samples could also be detected by analysis with mass spectrometry, as shown in Table 5 below. -
TABLE 5 Identification of Histones in Microvesicle Samples by OMS Gene Description Peps kDa HIST1H2BK Histone H2B type 1 - K 4 14 HIST2H2AC Histone H2A type 2- C 4 14 - Although the total protein load indicates that proteins from the microvesicle samples are loaded in equal amounts, U87 is identified as being the strongest in association with the well-known canonical marker CD63. However although widely regarded as an archetypic marker, CD63 is not strongly expressed on HELA or 293T.
- In summary, the data reveals that histone proteins, such as H2AX and γH2AX, are enriched in tumor-derived microvesicles. This suggests that histone proteins may be useful as tumor markers.
-
- Wubbolts R, Leckie R S, Veenhuizen P T, Schwarzmann G, M6bius W, Hoernschemeyer J, Slot J W, Geuze H J, Stoorvogel W. J Biol Chem. 2003 Mar. 28; 278(13):10963-72.
- Taylor, C. G., Atay, S., Tullis, R. H., Kesimer, M and Taylor, D. D. Anal. Biochem. 2012, 28(1): 44-53.
- Botelho et al. J. Proteome Res. 2010, 9, 2863-2870.
- Yates et al. Anal. Chem. 2004, 76, 4193-4201.
Claims (25)
1. A method of monitoring genotoxic stress in a test subject, comprising:
detecting the expression level of microvesicle-associated H2AX in a biological sample from the test subject, and
monitoring genotoxic stress in the subject based on the expression level of the microvesicle-associated H2AX.
2. The method of claim 1 , wherein the genotoxic stress is due to environmental contamination with genotoxins or radiation exposure.
3. The method of claim 1 , wherein the genotoxic stress is due to cancer treatment.
4. The method of claim 3 , wherein the cancer treatment comprises exposure to radiation.
5. The method of claim 3 , wherein the cancer treatment comprises administration of an anti-cancer agent selected from the group consisting of a platinum analogue, a tetrazine, an anti-metabolite, a plant alkaloid or terpenoid, a cytotoxic antibiotic, a DNA alkylating agent, or a type I topoisomerase inhibitor.
6-10. (canceled)
11. The method of claim 3 , further comprising detecting the expression level of microvesicle-associated H2AX in a biological sample from the test subject at a plurality of time points following administration of the cancer treatment.
12. The method of claim 3 , wherein monitoring the genotoxic stress comprises comparing the expression level of microvesicle-associated H2AX in the biological sample from the test subject with the expression level of H2AX in a biological sample from a control subject that is not given the cancer treatment.
13. The method of claim 12 , wherein a higher level of expression of microvesicle-associated H2AX in the biological sample from the test subject compared to the level of expression of microvesicle-associated H2AX in the biological sample from the control subject indicates that the cancer treatment is inducing genotoxic stress.
14. The method of claim 3 , wherein monitoring genotoxic stress comprises evaluating the efficacy of cancer treatment.
15. The method of claim 14 , wherein evaluating the efficacy of the cancer treatment in the test subject comprises comparing the expression level of microvesicle-associated H2AX in the biological sample from the test subject with the expression level of microvesicle-associated H2AX in biological samples from a plurality of control subjects.
16-17. (canceled)
18. The method of claim 15 , further comprising a step of deriving a score from the comparison of the expression level of microvesicle-associated H2AX in the biological sample from the test subject with the expression level of microvesicle-associated H2AX in the biological samples from the plurality of control subjects, wherein the score indicates a level of similarity between the expression level of microvesicle-associated H2AX in the biological sample from the test subject and the expression level of microvesicle-associated H2AX in the biological samples from the plurality of control subjects.
19. (canceled)
20. The method of claim 18 , wherein the score is a correlation coefficient.
21. The method of claim 3 , wherein the cancer comprises a solid tumor.
22. The method of claim 3 , wherein the cancer is selected from the group consisting of pancreatic, ovarian, adenocarcinoma, prostate, breast, brain, head, neck, and lymphoma cancers.
23-24. (canceled)
25. The method of claim 1 , wherein the biological sample is selected from the group consisting of plasma, serum, cerebrospinal fluid, urine, tears, milk, lymph fluid, synovial fluid, bronchoalveolar lavage, amniotic fluid, saliva, ocular fluid, ascites, and respiratory droplets.
26. The method of claim 1 , wherein detecting the expression level of microvesicle-associated H2AX comprises the use of ELISA, flow cytometry, or liquid chromatography-mass spectrometry.
27. The method of claim 1 , wherein detecting the expression level of microvesicle-associated H2AX comprises detecting binding of H2AX to an microvesicle-associated H2AX-specific antibody.
28-29. (canceled)
30. The method of claim 3 , further comprising a step of isolating cancer-derived microvesicles from the biological sample prior to detecting the expression level of microvesicle-associated H2AX.
31. The method of claim 30 , wherein isolating microvesicles from the biological sample prior to detecting the expression level of microvesicle-associated H2AX comprises:
contacting the biological sample with a cancer-derived microvesicle-specific reagent, wherein the biological sample comprises microvesicles and the reagent binds to microvesicles;
contacting the microvesicles with a tissue-specific reagent; and
isolating the microvesicles derived from the tissue.
32. The method of claim 1 , wherein the H2AX is γH2AX.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/058,683 US20230204593A1 (en) | 2013-03-14 | 2022-11-23 | Microvesicle histone h2ax as a biomarker for genotoxic stress |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361785552P | 2013-03-14 | 2013-03-14 | |
PCT/US2014/028079 WO2014152873A1 (en) | 2013-03-14 | 2014-03-14 | Microvesicle histone h2ax as a biomarker for genotoxic stress |
US201514774105A | 2015-09-09 | 2015-09-09 | |
US18/058,683 US20230204593A1 (en) | 2013-03-14 | 2022-11-23 | Microvesicle histone h2ax as a biomarker for genotoxic stress |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/028079 Continuation WO2014152873A1 (en) | 2013-03-14 | 2014-03-14 | Microvesicle histone h2ax as a biomarker for genotoxic stress |
US14/774,105 Continuation US11513125B2 (en) | 2013-03-14 | 2014-03-14 | Microvesicle histone H2AX as a biomarker for genotoxic stress |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230204593A1 true US20230204593A1 (en) | 2023-06-29 |
Family
ID=51581340
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/774,105 Active 2034-12-15 US11513125B2 (en) | 2013-03-14 | 2014-03-14 | Microvesicle histone H2AX as a biomarker for genotoxic stress |
US18/058,683 Pending US20230204593A1 (en) | 2013-03-14 | 2022-11-23 | Microvesicle histone h2ax as a biomarker for genotoxic stress |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/774,105 Active 2034-12-15 US11513125B2 (en) | 2013-03-14 | 2014-03-14 | Microvesicle histone H2AX as a biomarker for genotoxic stress |
Country Status (3)
Country | Link |
---|---|
US (2) | US11513125B2 (en) |
EP (1) | EP2971282B1 (en) |
WO (1) | WO2014152873A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2971282B1 (en) * | 2013-03-14 | 2018-09-19 | Pioma Inc. | Microvesicle histone h2ax as a biomarker for genotoxic stress |
FR3040175A1 (en) * | 2015-08-19 | 2017-02-24 | Neolys Diagnotics | PREDICTIVE INDIVIDUAL METHOD OF GENOTOXIC EFFECTS OF CHEMICAL OR BIOCHEMICAL AGENTS, BREAKING DNA |
FR3040176A1 (en) * | 2015-08-19 | 2017-02-24 | Neolys Diagnotics | PREDICTIVE METHOD OF EXCESS DOSE OF INDEXED CONTRAST PRODUCTS DURING RADIODIAGNOSTIC EXAMINATIONS AND EVALUATION OF EXCESS BIOLOGICAL DOSE |
CN106381329B (en) * | 2016-08-29 | 2019-07-26 | 北京泱深生物信息技术有限公司 | The diagnosis and treatment target of C18orf8 gene and its expression product as hypopharyngeal cancer |
US11578370B2 (en) * | 2017-02-15 | 2023-02-14 | Institute For Cancer Research | Methods for diagnosis and treatment of patients having solid tumors |
US20220381782A1 (en) * | 2021-06-01 | 2022-12-01 | City University | Method of isolating and detecting exosomal biomarkers of glioblastoma malignancy |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130203081A1 (en) * | 2010-04-13 | 2013-08-08 | Janusz Rak | Tumor cell-derived microvesicles |
US20150140123A1 (en) * | 2012-06-13 | 2015-05-21 | Merck Patent Gmbh | Protein expression analyses for identifying genotoxic compounds |
US11513125B2 (en) * | 2013-03-14 | 2022-11-29 | Pioma, Inc. | Microvesicle histone H2AX as a biomarker for genotoxic stress |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2788780B1 (en) | 1999-01-27 | 2001-03-30 | Ap Cells Inc | PROCESS FOR THE PREPARATION OF MEMBRANE VESICLES |
US6812023B1 (en) | 2000-04-27 | 2004-11-02 | Anosys, Inc. | Methods of producing membrane vesicles |
EP2202522A1 (en) * | 2008-12-23 | 2010-06-30 | Universiteit Leiden | Methods for immobilizing microvesicles, means and methods for detecting them, and uses thereof |
US20140045915A1 (en) * | 2010-08-31 | 2014-02-13 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
JP5894664B2 (en) * | 2011-06-06 | 2016-03-30 | メディパン・ゲーエムベーハー | Method and system for automatically determining immunofluorescent lesions by cell-based immunofluorescence assay using synthetic calibration particles |
-
2014
- 2014-03-14 EP EP14767965.8A patent/EP2971282B1/en active Active
- 2014-03-14 US US14/774,105 patent/US11513125B2/en active Active
- 2014-03-14 WO PCT/US2014/028079 patent/WO2014152873A1/en active Application Filing
-
2022
- 2022-11-23 US US18/058,683 patent/US20230204593A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130203081A1 (en) * | 2010-04-13 | 2013-08-08 | Janusz Rak | Tumor cell-derived microvesicles |
US20150140123A1 (en) * | 2012-06-13 | 2015-05-21 | Merck Patent Gmbh | Protein expression analyses for identifying genotoxic compounds |
US11513125B2 (en) * | 2013-03-14 | 2022-11-29 | Pioma, Inc. | Microvesicle histone H2AX as a biomarker for genotoxic stress |
Non-Patent Citations (1)
Title |
---|
uminex xMAP technology (retrieved from https://www.ablinc.com/immunology-services/luminex/ on 7/8/2017) (Year: 2017) * |
Also Published As
Publication number | Publication date |
---|---|
EP2971282A4 (en) | 2017-01-18 |
WO2014152873A1 (en) | 2014-09-25 |
US20160041175A1 (en) | 2016-02-11 |
EP2971282B1 (en) | 2018-09-19 |
EP2971282A1 (en) | 2016-01-20 |
US11513125B2 (en) | 2022-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230204593A1 (en) | Microvesicle histone h2ax as a biomarker for genotoxic stress | |
Theodoraki et al. | Clinical significance of PD-L1+ exosomes in plasma of head and neck cancer patients | |
CN101036055B (en) | Detection of elevated levels of Her-2/neu protein on circulating cancer cells and treatment | |
ES2257087T3 (en) | METHOD AND REAGENTS FOR THE DETECTION OF CANCER. | |
Peterson et al. | Ascites analysis by a microfluidic chip allows tumor-cell profiling | |
ES2701250T3 (en) | Isolation procedure of exosomes | |
US9528998B2 (en) | Methods and reagents for diagnosing rheumatoid arthrtis | |
EP1864133A1 (en) | Method for cancer prognosis using cellular folate vitamin receptor quantification | |
WO2007121465A2 (en) | Detection of proteins from circulating neoplastic cells | |
KR20100101109A (en) | Automated enumeration and characterization of circulating melanoma cells in blood | |
US20230160899A1 (en) | Use of tenascin-c as an extracellular marker of tumor-derived microparticles | |
Dubey et al. | Leucine zipper 4 autoantibody: a novel germ cell tumor and paraneoplastic biomarker | |
EP3102593B1 (en) | Fluorometric immunoassay for detection of anti-dsdna antibodies | |
Ko et al. | The glycoprotein CD147 defines miRNA‐enriched extracellular vesicles that derive from cancer cells | |
US20210231659A1 (en) | Detection and isolation of myeloid-derived suppressor cell subpopulations | |
CN102138074B (en) | ASC as a marker for lung cancer | |
Liu et al. | The potential diagnostic power of CD138+ microparticles from the plasma analysis for multiple myeloma clinical monitoring | |
US8524466B2 (en) | Microvesicle membrane protein and application thereof | |
CN112543871A (en) | Marker for pancreatic cancer diagnosis | |
JP7432578B2 (en) | Cancer markers and their uses | |
EP4062175A1 (en) | Methods for assessing efficacy of malt1 inhibitors using an nf-kb translocation assay | |
US20220323498A1 (en) | Assay for immune cell recovery | |
Miles et al. | Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas | |
Wang et al. | MALT1 Protease Regulates T-Cell Immunity via the mTOR Pathway in Oral Lichen Planus | |
CN111886501A (en) | Method for judging mental disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |